,regularMarketPrice,logo_url,52WeekChange,SandP52WeekChange,address1,algorithm,annualHoldingsTurnover,annualReportExpenseRatio,ask,askSize,averageDailyVolume10Day,averageVolume,averageVolume10days,beta,beta3Year,bid,bidSize,bookValue,category,circulatingSupply,city,companyOfficers,country,currency,currentPrice,currentRatio,dateShortInterest,dayHigh,dayLow,debtToEquity,dividendRate,dividendYield,earningsGrowth,earningsQuarterlyGrowth,ebitda,ebitdaMargins,enterpriseToEbitda,enterpriseToRevenue,enterpriseValue,exDividendDate,exchange,exchangeTimezoneName,exchangeTimezoneShortName,expireDate,fiftyDayAverage,fiftyTwoWeekHigh,fiftyTwoWeekLow,financialCurrency,fiveYearAverageReturn,fiveYearAvgDividendYield,floatShares,forwardEps,forwardPE,freeCashflow,fromCurrency,fullTimeEmployees,fundFamily,fundInceptionDate,gmtOffSetMilliseconds,grossMargins,grossProfits,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,industry,isEsgPopulated,lastCapGain,lastDividendDate,lastDividendValue,lastFiscalYearEnd,lastMarket,lastSplitDate,lastSplitFactor,legalType,longBusinessSummary,longName,market,marketCap,maxAge,maxSupply,messageBoardId,morningStarOverallRating,morningStarRiskRating,mostRecentQuarter,navPrice,netIncomeToCommon,nextFiscalYearEnd,numberOfAnalystOpinions,open,openInterest,operatingCashflow,operatingMargins,payoutRatio,pegRatio,phone,previousClose,priceHint,priceToBook,priceToSalesTrailing12Months,profitMargins,quickRatio,quoteType,recommendationKey,recommendationMean,regularMarketDayHigh,regularMarketDayLow,regularMarketOpen,regularMarketPreviousClose,regularMarketVolume,returnOnAssets,returnOnEquity,revenueGrowth,revenuePerShare,revenueQuarterlyGrowth,sector,sharesOutstanding,sharesPercentSharesOut,sharesShort,sharesShortPreviousMonthDate,sharesShortPriorMonth,shortName,shortPercentOfFloat,shortRatio,startDate,state,strikePrice,symbol,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,threeYearAverageReturn,toCurrency,totalAssets,totalCash,totalCashPerShare,totalDebt,totalRevenue,tradeable,trailingAnnualDividendRate,trailingAnnualDividendYield,trailingEps,twoHundredDayAverage,volume,volume24Hr,volumeAllCurrencies,website,yield,ytdReturn,zip,trailingPE,fax,address2
0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1,17.96,https://logo.clearbit.com/aa.com,0.19431591,0.29132175,1 Skyview Drive,,,,17.98,4000.0,33393990.0,34412306.0,33393990.0,1.667532,,17.96,2900.0,-11.486,,,Fort Worth,[],United States,USD,17.96,1.014,1639526400.0,18.36,17.93,,,,,,-4754999808.0,-0.19422,-9.215,1.79,43818917888.0,1580774400.0,NMS,America/New_York,EST,,18.9038,26.09,14.71,USD,,,641307009.0,-0.11,-163.27272,-1145750016.0,,119800.0,,,-18000000,-0.04542,-5536000000.0,0.0098,0.56364,,Airlines,0.0,,1580774400.0,0.1,1609372800.0,,,,,"American Airlines Group Inc., through its subsidiaries, operates as a network air carrier. The company provides scheduled air transportation services for passengers and cargo through its hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C., as well as through partner gateways in London, Madrid, Seattle/Tacoma, Sydney, and Tokyo. As of December 31, 2020, it operated a mainline fleet of 855 aircraft. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1930 and is headquartered in Fort Worth, Texas.",American Airlines Group Inc.,us_market,11629350912.0,1.0,,finmb_168569,,,1632960000.0,,-3239000064.0,1672444800.0,18.0,18.07,,-959000000.0,-0.28338,0.0,0.02,817 963 1234,18.07,2.0,,0.47499695,-0.13229,0.838,EQUITY,hold,3.1,18.36,17.93,18.07,18.07,20498933.0,-0.0661,,1.827,39.184,,Industrials,647513984.0,0.1582,102466793.0,1636934400.0,72512021.0,"American Airlines Group, Inc.",0.1776,2.39,,TX,,AAL,28.0,5.0,19.11,20.0,,,,14535999488.0,22.45,46655000576.0,24483000320.0,0.0,0.0,0.0,-5.184,20.83105,20498933.0,,,https://www.aa.com,,,76155,,,
2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3,5.6587,https://logo.clearbit.com/ao-inc.com,-0.36842108,0.26514983,13139 Jess Pirtle Boulevard,,,,5.67,900.0,440900.0,663193.0,440900.0,1.741298,,5.65,800.0,9.714,,,Sugar Land,[],United States,USD,5.6587,2.149,1638230400.0,5.685,5.6012,58.348,,,,,-30731000.0,-0.1467,-8.605,1.262,264443728.0,,NGM,America/New_York,EST,,6.3814,13.949,5.2,USD,,,26095186.0,-0.6,-9.431167,-15275375.0,,2682.0,,,-18000000,0.19523,50541000.0,0.07125,0.51268,,Semiconductors,False,,,,1609372800.0,,,,,"Applied Optoelectronics, Inc. designs, manufactures, and sells various fiber-optic networking products worldwide. It offers optical modules, lasers, subassemblies, transmitters and transceivers, and turn-key equipment, as well as headend, node, and distribution equipment. The company sells its products to internet data center operators, cable television and telecom equipment manufacturers, and internet service providers through its direct and indirect sales channels. Applied Optoelectronics, Inc. was incorporated in 1997 and is headquartered in Sugar Land, Texas.","Applied Optoelectronics, Inc.",us_market,154468928.0,1.0,,finmb_1043391,,,1632960000.0,,-53061000.0,1672444800.0,7.0,5.61,,-25487000.0,-0.26877,0.0,-0.55,281 295 1800,5.64,2.0,0.5825304,0.7373852,-0.2533,0.937,EQUITY,hold,2.7,5.685,5.6012,5.61,5.64,43337.0,-0.07329,-0.20056,-0.305,8.056,,Technology,27297600.0,0.1251,3416138.0,1635465600.0,4494518.0,"Applied Optoelectronics, Inc.",0.1496,2.79,,TX,,AAOI,57.0,6.5,15.36,8.0,,,,43534000.0,1.595,154019008.0,209482000.0,False,,,-2.041,7.416575,43337.0,,,https://www.ao-inc.com,,,77478,,,
4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5,177.57,https://logo.clearbit.com/apple.com,0.3770188,0.29132175,One Apple Park Way,,,,177.59,1200.0,98069820.0,89457731.0,98069820.0,1.203116,,177.52,800.0,3.841,,,Cupertino,[],United States,USD,177.57,1.075,1639526400.0,179.23,177.26,216.392,0.88,0.0049,0.662,0.622,120233000960.0,0.32867,24.931,8.194,2997502869504.0,1636070400,NMS,America/New_York,EST,,161.5314,182.13,116.21,USD,,1.2,16389662475.0,6.18,28.733011,73295003648.0,,154000.0,,,-18000000,0.41779,152836000000.0,0.0007,0.58833003,,Consumer Electronics,False,,1636070400,0.22,1632528000.0,,1598832000,4:1,,"Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. It also sells various related services. In addition, the company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; AirPods Max, an over-ear wireless headphone; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, HomePod, and iPod touch. Further, it provides AppleCare support services; cloud services store services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. Additionally, the company offers various services, such as Apple Arcade, a game subscription service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.",Apple Inc.,us_market,2913284653056.0,1.0,,finmb_24937,,,1632528000.0,,94679998464.0,1695600000.0,42.0,178.085,,104037998592.0,0.29782,0.1515,1.99,408 996 1010,178.2,2.0,46.23015,7.963776,0.25882,0.91,EQUITY,buy,1.8,179.23,177.26,178.085,178.2,59615456.0,0.20179,1.47443,0.288,21.904,,Technology,16406400000.0,0.0069,113277024.0,1636934400.0,99688619.0,Apple Inc.,0.0069,1.0,,CA,,AAPL,210.0,128.01,175.76,175.0,,,,62639001600.0,3.818,136521998336.0,365817004032.0,False,0.85,0.004769922,5.61,143.66846,59615456.0,,,https://www.apple.com,,,95014,31.652407,,
6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7,91.8,https://logo.clearbit.com/atlasairworldwide.com,0.6770016,0.26514983,2000 Westchester Avenue,,,,91.78,1100.0,553630.0,544080.0,553630.0,1.117922,,91.48,800.0,90.414,,,Purchase,[],United States,USD,91.8,0.8,1638230400.0,92.57,91.415,99.882,,,0.406,0.614,944595968.0,0.24856001,4.781,1.188,4516412416.0,,NMS,America/New_York,EST,,86.128,95.0,50.22,USD,,,25170721.0,12.95,7.0888033,196027008.0,,4061.0,,,-18000000,0.33448002,1092115000.0,0.06361,1.11653,,Airports & Air Services,False,,,,1609372800.0,,,,,"Atlas Air Worldwide Holdings, Inc., through its subsidiaries, provides outsourced aircraft and aviation operating services. It operates through three segments: ACMI, Charter, and Dry Leasing. The company offers outsourced cargo and passenger aircraft operating solutions, including contractual service arrangements, such as the provision of aircraft; and value-added services, including crew, maintenance, and insurance to aircraft and other customers. It also provides cargo and passenger aircraft charter services to the U.S. Military Air Mobility Command, charter brokers, freight forwarders, direct shippers, airlines, sports teams and fans, and private charter customers; and cargo and passenger aircraft and engines dry leasing services. In addition, the company offers administrative and management support services, and flight simulator training services. It also serves express delivery providers, e-commerce retailers, and airlines. The company has operations in Africa, Asia, Australia, Europe, the Middle East, North America, and South America. Atlas Air Worldwide Holdings, Inc. was founded in 1992 and is headquartered in Purchase, New York.","Atlas Air Worldwide Holdings, Inc.",us_market,2664797952.0,1.0,,finmb_340272,,,1632960000.0,,500544992.0,1672444800.0,7.0,92.57,,835766976.0,0.16884,0.0,0.52,914 701 8000,91.95,2.0,1.0153295,0.70120597,0.13171,0.732,EQUITY,buy,2.0,92.57,91.415,92.57,91.95,22983.0,0.066360004,0.21566999,0.255,133.423,,Industrials,29028300.0,0.1289,3741425.0,1635465600.0,3416427.0,Atlas Air Worldwide Holdings,0.1717,6.89,,NY,,AAWW,140.0,82.0,105.57,105.0,,,,773910976.0,26.661,2621171968.0,3800306944.0,False,,,16.919,74.4423,22983.0,,,https://www.atlasairworldwide.com,,,10577-2543,5.425853,914 701 8333,
8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18,353.785,https://logo.clearbit.com/abiomed.com,0.12559521,0.26514983,22 Cherry Hill Drive,,,,353.79,800.0,303570.0,242285.0,303570.0,1.270649,,352.98,1400.0,30.432,,,Danvers,[],United States,USD,353.785,7.643,1638230400.0,354.02,350.11,0.567,,,-0.088,-0.085,288176000.0,0.29598,53.377,15.798,15381965824.0,,NMS,America/New_York,EST,,336.7592,387.4,261.27,USD,,,44590270.0,5.01,70.61577,170232128.0,,1725.0,,,-18000000,0.81897,685615000.0,0.020610001,0.92825997,,Medical Devices,False,,,,1617148800.0,,970444800,2:1,,"Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.","Abiomed, Inc.",us_market,16096332800.0,1.0,,finmb_247589,,,1632960000.0,,149152000.0,1680220800.0,5.0,353.8,,281540992.0,0.26919,0.0,8.0,978 646 1400,352.21,2.0,11.625427,16.532204,0.15319,6.491,EQUITY,buy,2.5,354.02,350.11,353.8,352.21,67786.0,0.114630006,0.116210006,0.183,21.494,,Healthcare,45497500.0,0.020399999,928904.0,1635465600.0,817691.0,"ABIOMED, Inc.",0.0234,3.53,,MA,,ABMD,425.0,269.0,379.8,410.0,,,,650558976.0,14.299,7854000.0,973635008.0,False,,,3.257,325.42035,67786.0,,,https://www.abiomed.com,,,01923,108.62297,978 777 8411,
19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21,24.3,https://logo.clearbit.com/acadia-pharm.com,-0.54297537,0.26514983,12830 El Camino Real,,,,24.51,800.0,3156150.0,1635874.0,3156150.0,0.568831,,24.26,800.0,3.528,,,San Diego,[],United States,USD,24.3,7.265,1638230400.0,24.58,23.37,11.611,,,,,-136496992.0,-0.28773,-25.143,7.234,3431906048.0,,NMS,America/New_York,EST,,20.2492,55.85,15.68,USD,,,118028641.0,-0.9,-27.0,-37918000.0,,570.0,,,-18000000,0.57067,154875000.0,0.00366,0.91266,,Biotechnology,False,,,,1609372800.0,,,,,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.",ACADIA Pharmaceuticals Inc.,us_market,3906370560.0,1.0,,finmb_683713,,,1632960000.0,,-191536000.0,1672444800.0,19.0,23.85,,-130028000.0,-0.29542,0.0,-0.84,858 558 2871,23.92,2.0,6.8877544,8.234444,-0.40375,6.824,EQUITY,hold,2.7,24.58,23.37,23.85,23.92,2036266.0,-0.11576,-0.31351998,0.092,2.973,,Healthcare,160756000.0,0.0361,5805076.0,1635465600.0,7830578.0,ACADIA Pharmaceuticals Inc.,0.0585,4.51,,CA,,ACAD,42.0,18.0,28.89,30.0,,,,540291008.0,3.361,65827000.0,474393984.0,False,,,-1.2,20.98325,2036266.0,,,https://www.acadia-pharm.com,,,92130,,858 212 0513,Suite 400
22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
24,15.85,https://logo.clearbit.com/adicetbio.com,0.13946795,0.2505386,500 Boylston Street,,,,16.5,800.0,6313640.0,1085157.0,6313640.0,,,16.35,1200.0,6.798,,,Boston,[],United States,USD,15.85,9.935,1638230400.0,16.1099,14.08,9.453,,,,,-45552000.0,0.0,-7.35,34.616,334802880.0,,NGM,America/New_York,EST,,10.0706,17.8,6.25,USD,,,12770356.0,-2.26,-7.0132747,-36551624.0,,81.0,,,-18000000,1.0,17903000.0,0.11422,0.6085,,Biotechnology,False,,,,1609372800.0,,1600214400,1:7,,"Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.","Adicet Bio, Inc.",us_market,620419712.0,1.0,,finmb_310073311,,,1632960000.0,,-55144000.0,1672444800.0,7.0,14.35,,-50953000.0,-4.8635197,0.0,-0.25,857 315 5528,14.24,2.0,2.3315682,64.14596,0.0,9.731,EQUITY,strong_buy,1.4,16.1099,14.08,14.35,14.24,907464.0,-0.14425999,-0.33005002,0.132,0.353,,Healthcare,38205700.0,0.0094,301386.0,1635465600.0,413383.0,"Adicet Bio, Inc.",0.0219,2.73,,MA,,ACET,34.0,25.0,31.0,33.0,,,,192226000.0,6.015,20535000.0,9672000.0,False,,,-2.013,10.486175,907464.0,,,https://www.adicetbio.com,,,02116,,,13th Floor
25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27,42.105,https://logo.clearbit.com/archgroup.com,0.25749195,0.2505386,Waterloo House,,,,42.18,800.0,1682820.0,1889847.0,1682820.0,0.903896,,42.17,800.0,32.564,,,Pembroke,[],Bermuda,USD,42.105,2.207,1638230400.0,42.8,41.93,20.333,,,-0.02,0.002,2384026880.0,0.25553,6.652,1.7,15859147776.0,,NMS,America/New_York,EST,,42.506,44.53,31.23,USD,,,338361995.0,3.8,11.080263,968958400.0,,4500.0,,,-18000000,0.36581,2830834000.0,0.029240001,1.00387,,Insurance—Diversified,False,,,,1609372800.0,,1529539200,3:1,,"Arch Capital Group Ltd., together with its subsidiaries, provides insurance, reinsurance, and mortgage insurance products worldwide. The company's Insurance segment offers primary and excess casualty coverages; loss sensitive primary casualty insurance programs; collateral protection, debt cancellation, and service contract reimbursement products; directors' and officers' liability, errors and omissions liability, employment practices and fiduciary liability, crime, professional indemnity, and other financial related coverages; medical professional and general liability insurance coverages; and workers' compensation and umbrella liability, as well as commercial automobile, and inland marine products. It also provides property, energy, marine, and aviation insurance; travel insurance; accident, disability, and medical plan insurance coverages; captive insurance programs; employer's liability; and contract and commercial surety coverages. This segment markets its products through a group of licensed independent retail and wholesale brokers. Its Reinsurance segment provides reinsurance for third party liability and workers' compensation exposures; marine and aviation reinsurance; surety, accident and health, workers' compensation catastrophe, agriculture, trade credit, and political risk products; reinsurance protection for catastrophic losses, and personal lines and commercial property exposures; life reinsurance; casualty clash; and risk management solutions. This segment markets its reinsurance products through brokers. The company's Mortgage segment offers direct mortgage insurance and mortgage reinsurance. The company was founded in 1995 and is based in Pembroke, Bermuda.",Arch Capital Group Ltd.,us_market,16258172928.0,1.0,,finmb_346919,,,1632960000.0,,2013464960.0,1672444800.0,,42.69,,3182606080.0,0.24813,0.0,0.31,,43.22,2.0,1.2929922,1.7426258,0.22264,1.188,EQUITY,none,,42.8,41.93,42.69,43.22,1021629.0,0.033069998,0.16614,-0.091,23.461,,Financial Services,386134016.0,0.0069999998,2693028.0,1635465600.0,3086954.0,Arch Capital Group Ltd.,0.0072000003,1.29,,,,ACGL,,,,,,,,4323366912.0,11.244,2724148992.0,9329697792.0,False,,,4.961,40.1446,1021629.0,,,https://www.archgroup.com,,,HM 08,8.4872,441 278 9255,Ground Floor 100 Pitts Bay Road
28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
30,31.2225,https://logo.clearbit.com/aciworldwide.com,-0.22557956,0.22927392,600 Brickell Avenue,,,,30.98,1100.0,713650.0,795409.0,713650.0,1.076363,,30.53,800.0,10.172,,,Miami,[],United States,USD,31.2225,1.259,1636934400.0,31.3,30.36,95.593,,,-0.099,-0.132,231678000.0,0.17948,19.409,3.484,4496632320.0,,NMS,America/New_York,EST,,31.3792,43.23,28.39,USD,,,107131252.0,1.29,24.20349,298295616.0,,3768.0,,,-18000000,0.51456,676163000.0,0.01074,0.98253995,,Software—Infrastructure,False,,,,1609372800.0,,1405036800,3:1,,"ACI Worldwide, Inc., a software company, develops, markets, installs, and supports a range of software products and solutions for facilitating electronic payments to banks, financial intermediaries, merchants, and billers worldwide. The company offers ACI Acquiring, a merchant management system to deliver digital innovation, improve fraud prevention, and reduce interchange fees; ACI Issuing, a digital payments issuing solution; and ACI Enterprise Payments Platform that provides payment processing and orchestration capabilities for digital payments. It also provides ACI Low Value Real-Time Payments, a platform for processing real-time payments; and ACI High Value Real-Time Payments, a payments engine that offers multi-bank, multi-currency, 24x7 payment processing, and SWIFT messaging. In addition, the company offers ACI Omni Commerce, a scalable, omni-channel payment processing platform; ACI Secure eCommerce solution; ACI Fraud Management, a real-time approach to fraud management; ACI Digital Business Banking, a cloud-based digital banking platform; and ACI Speedpay, an integrated suite of digital billing, payment, disbursement, and communication services. The company offers electronic bill presentment and payment services to consumer finance, insurance, healthcare, higher education, utility, government, and mortgage sectors; implementation services, including product installations and configurations, and custom software modifications; and business and technical consultancy, on-site support, product education, and testing services, as well as distributes or acts as a sales agent for software developed by third parties. It markets its products under the ACI Worldwide brand. ACI Worldwide, Inc. has a strategic partnership with RocketFuel Blockchain, Inc. The company was formerly known as Transaction Systems Architects, Inc. and changed its name to ACI Worldwide, Inc. in July 2007. The company was founded in 1975 and is based in Miami, Florida.","ACI Worldwide, Inc.",us_market,3670704384.0,1.0,,finmb_35695,,,1632960000.0,,85466000.0,1672444800.0,5,30.52,,292142016.0,0.13325,0.0,2.22,305 894 2200,29.73,2.0,3.0694554,2.843715,0.06621,0.549,EQUITY,buy,1.6,31.3,30.36,30.52,29.73,129335.0,0.03404,0.07373,0.003,10.994,,Technology,117566000.0,0.0179,2106577.0,1634256000.0,2458458.0,"ACI Worldwide, Inc.",0.020499999,2.12,,FL,,ACIW,46,40,42.8,42,,,,141482000.0,1.203,1142864000.0,1290813056.0,False,,,0.716,35.4618,129335.0,,,https://www.aciworldwide.com,,,33131,43.606842,,Suite 1500
31,73.11,https://logo.clearbit.com/axcelis.com,1.5192308,0.27608383,108 Cherry Hill Drive,,,,73.77,1000.0,400230.0,389451.0,400230.0,1.48935,,73.65,800.0,15.317,,,Beverly,[],United States,USD,73.11,4.156,1639526400.0,74.4599,71.64,10.883,,,1.531,1.551,100202000.0,0.17308001,22.239,3.849,2228354304.0,,NMS,America/New_York,EST,,61.4722,74.4599,28.45,USD,,,30847044.0,3.66,19.97541,62048876.0,,1004.0,,,-18000000,0.43171,198584000.0,0.01879,0.8935,,Semiconductor Equipment & Materials,False,,,,1609372800.0,,1467331200,1:4,,"Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. The company was founded in 1978 and is headquartered in Beverly, Massachusetts.","Axcelis Technologies, Inc.",us_market,2435425792.0,1.0,,finmb_416350,,,1632960000.0,,77575000.0,1672444800.0,6,73.4,,106117000.0,0.16377,0.0,1.37,978 787 4000,73.36,2.0,4.773128,4.2066765,0.13399,2.546,EQUITY,buy,1.8,74.4599,71.64,73.4,73.36,725801.0,0.09105,0.15956001,0.6,17.22,,Technology,33311800.0,0.029000001,966290.0,1636934400.0,718138.0,"Axcelis Technologies, Inc.",0.035,2.19,,MA,,ACLS,87,73,79.33,78,,,,271084992.0,8.138,55687000.0,578942976.0,False,,,2.25,47.31575,725801.0,,,https://www.axcelis.com,,,01915-1053,32.493332,978 787 3000,
32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
33,2.73,https://logo.clearbit.com/acorda.com,-0.43201756,0.2652452,420 Saw Mill River Road,,,,2.74,800.0,152700.0,148979.0,152700.0,0.517402,,2.64,2900.0,14.701,,,Ardsley,[],United States,USD,2.73,1.422,1638230400.0,2.73,2.58,114.898,,,,,-49756000.0,-0.38196,-3.654,1.396,181810448.0,,NMS,America/New_York,EST,,3.6156,8.66,2.34,USD,,,10274315.0,-0.96,-2.84375,7839250.0,,167.0,,,-18000000,0.54042,96785000.0,0.01615,0.28619,,Drug Manufacturers—Specialty & Generic,False,,,,1609372800.0,,1609718400,1:6,,"Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.","Acorda Therapeutics, Inc.",us_market,30582006.0,1.0,,finmb_24246,,,1632960000.0,,-166435008.0,1672444800.0,1,2.59,,-43140000.0,-0.65419,0.0,,914 347 4300,2.59,4.0,0.18570165,0.23476943,-1.27767,0.729,EQUITY,buy,2,2.73,2.58,2.59,2.59,13411.0,-0.09054,-0.69637,-0.407,13.337,,Healthcare,11202200.0,0.084,940564.0,1635465600.0,434957.0,"Acorda Therapeutics, Inc.",0.0853,4.48,,NY,,ACOR,10,10,10,10,,,,36168000.0,3.23,188979008.0,130264000.0,False,,,-17.041,4.22105,13411.0,,,https://www.acorda.com,,,10502,,914 347 4560,
34,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
35,0.5602,https://logo.clearbit.com/acelrx.com,-0.60800004,0.29132175,25821 Industrial Boulevard,,,,0.5552,3100.0,1451290.0,1057469.0,1451290.0,0.742857,,0.55,900.0,-0.361,,,Hayward,[],United States,USD,0.5602,3.032,1639526400.0,0.5799,0.508,,,,,,-35140000.0,0.0,-0.859,8.497,30198902.0,,NGM,America/New_York,EST,,0.6992,2.94,0.46,USD,,,117336702.0,-0.23,-2.435652,-19156500.0,,54.0,,,-18000000,-1.18458,-4633000.0,0.01695,0.18372,,Drug Manufacturers—Specialty & Generic,False,,,,1609372800.0,,,,,"AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Hayward, California.","AcelRx Pharmaceuticals, Inc.",us_market,66842500.0,1.0,,finmb_33172220,,,1632960000.0,,-36100000.0,1672444800.0,3,0.51,,-28325000.0,-10.42037,0.0,,650 216 3500,0.4903,4.0,,18.807682,0.0,2.862,EQUITY,buy,2,0.5799,0.508,0.51,0.4903,3264017.0,-0.33438,,0.361,0.032,,Healthcare,119319000.0,0.0215,2570769.0,1636934400.0,3151098.0,"AcelRx Pharmaceuticals, Inc.",0.0218,2.0,,CA,,ACRX,4.5,4,4.17,4,,,,48699000.0,0.408,20396000.0,3554000.0,False,,,-0.325,1.1135,3264017.0,,,https://www.acelrx.com,,,94545,,,Suite 400
36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
37,1.26,https://logo.clearbit.com/acastipharma.com,-0.609375,0.29132175,3009 boulevard de la Concorde East,,,,1.26,1000.0,7253910.0,1464530.0,7253910.0,1.427471,,1.24,800.0,2.579,,,Laval,[],Canada,USD,1.26,12.186,1639526400.0,1.3497,1.23,0.038,,,,,-6900000.0,0.0,-0.669,23.537,4613229.0,,NCM,America/New_York,EST,,1.437,9.76,1.04,USD,,,33202851.0,-0.09,-13.999999,-5023875.0,,,,,-18000000,0.61224,120000.0,0.17104,0.0044400003,,Biotechnology,False,,,,1617148800.0,,1630368000,1:8,,"Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.",Acasti Pharma Inc.,us_market,55803132.0,1.0,,finmb_47663822,,,1632960000.0,,-11003000.0,1680220800.0,1,1.23,,-15479000.0,-37.56633,0.0,,,1.25,4.0,0.48856145,284.70987,0.0,11.529,EQUITY,strong_buy,1,1.3497,1.23,1.23,1.25,874835.0,-0.06888,-0.17879999,,0.008,,Healthcare,44288200.0,0.02,884403.0,1636934400.0,941919.0,"Acasti Pharma, Inc.",0.02,2.52,,QC,,ACST,6.01,6.01,6.01,6.01,,,,50790000.0,1.147,43000.0,196000.0,False,,,-0.464,3.0624,874835.0,,,https://www.acastipharma.com,,,H7E 2B5,,,Suite 102
38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
39,5.22,https://logo.clearbit.com/acaciaresearch.com,0.2731707,0.2682916,767 3rd Avenue,,,,5.5,800.0,343110.0,404485.0,343110.0,0.347532,,0.0,800.0,4.515,,,New York,[],United States,USD,5.22,3.274,1638230400.0,5.22,5.22,63.224,,,1.673,1.337,-14784000.0,-0.50686,8.987,-4.555,-132862536.0,1446595200,NMS,America/New_York,EST,,5.3166,9.09,3.78,USD,,,48526123.0,0.23,22.69565,13316625.0,,20.0,,,-18000000,0.49618998,9639000.0,0.04285,0.64304,,Specialty Business Services,False,,1446595200,0.125,1609372800.0,,,,,"Acacia Research Corporation, together with its subsidiaries, intends to acquire undervalued businesses primarily in technology, life sciences, industrial, and financial services segments in the United States. The company also invests in intellectual property and related absolute return assets, as well as engages in the licensing and enforcement of patented technologies. Acacia Research Corporation was incorporated in 1993 and is based in New York, New York.",Acacia Research Corporation,us_market,258869712.0,1.0,,finmb_4058466,,,1632960000.0,,6438000.0,1672444800.0,,5.12,,-32771000.0,-0.79447,0.0,-0.16,949 480 8300,5.22,2.0,1.1561462,8.875127,0.84791,3.251,EQUITY,none,,5.22,5.22,5.12,5.22,1782.0,-0.024619998,0.096920006,-0.919,0.599,,Industrials,49591900.0,0.0166,824258.0,1635465600.0,1550775.0,Acacia Research Corporation,0.016900001,2.4,,NY,,ACTG,,,,,,,,642732992.0,12.96,183956000.0,29168000.0,False,0.125,0.023946362,0.132,5.8648,1782.0,,,https://www.acaciaresearch.com,,,10017,39.545452,,Suite 602
40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
41,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,105.95,,,,,,,,127.14,4000.0,4573550.0,3818011.0,4573550.0,,1,106.1,900.0,,,,,[],,USD,,,,106.3982,105.885,,,,,,,,,,,,NGM,America/New_York,EST,,105.1814,107.46,89.44,,0.1491,,,,,,,,iShares,1206489600,-18000000,,,,,,,False,,,,,,,,Exchange Traded Fund,"The investment seeks to track the investment results of the MSCI ACWI composed of large- and mid-capitalization developed and emerging market equities.
 The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.",iShares MSCI ACWI ETF,us_market,,1.0,,finmb_42958701,,,,105.92,,,,106.12,,,,,,800-474-2737,106.0787,2.0,,,,,ETF,,,106.3982,105.885,106.12,106.0787,2156044.0,,,,,,,,,,,,iShares MSCI ACWI Index Fund,,,,,,ACWI,,,,,0.1848,,16854806528,,,,,False,,,,101.8748,2156044.0,,,,0.0139,,,,,
43,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
45,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,567.06,https://logo.clearbit.com/adobe.com,0.17552638,0.29132175,345 Park Avenue,,,,570.0,1800.0,4131490.0,2703096.0,4131490.0,1.060779,,567.06,1400.0,31.086,,,San Jose,[],United States,USD,567.06,1.248,1639526400.0,570.17,565.22,31.581,,,-0.445,-0.452,6579333120.0,0.41681,41.106,17.133,270447280128,1111622400,NMS,America/New_York,EST,,635.755,699.54,420.78,USD,,,474619600.0,16.25,34.896,,,,,,-18000000,0.88185,13920000000.0,0.00312,0.85459,,Software—Infrastructure,False,,1111622400,0.0065,1638489600,,1116892800,2:1,,"Adobe Inc. operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, teams, and enterprises to create, publish, promote, and monetize their digital content. Its flagship product is Creative Cloud, a subscription service that allows customer to download and access the latest versions of its creative products. This segment serves content creators, experience designers, app developers, enthusiasts, students, social media users, and creative professionals; and marketing departments and agencies, companies, and publishers. The company's Digital Experience segment offers products, services, and solutions for creating, managing, executing, measuring, monetizing, and optimizing customer experiences from analytics to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, marketing executives, information management and technology executives, product development executives, and sales and support executives. Its Publishing and Advertising segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end users through app stores and through its website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and OEMs. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. The company was founded in 1982 and is headquartered in San Jose, California.",Adobe Inc.,us_market,269807140864,1.0,,finmb_24321,,,1638489600,,4822000128,1701561600,28,570.0,,,0.36756,0,2.69,408 536 6000,570.53,2.0,18.241652,17.092628,0.30548,1.107,EQUITY,buy,1.8,570.17,565.22,570.0,570.53,1452719.0,0.14076,0.34368,0.2,33.092,,Technology,475800000.0,0.0101,4795281.0,1636934400.0,4143342.0,Adobe Inc.,0.0101,1.59,,CA,,ADBE,750,560,671.75,680,,,,5798000128.0,12.181,4672999936.0,15784999936.0,False,,,10.02,583.8482,1452719.0,,,https://www.adobe.com,,,95110-2704,56.59281,408 537 6000,
47,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,6.86,https://logo.clearbit.com/advancedemissionssolutions.com,0.25641024,0.2918527,8051 E. Maplewood Avenue,,,,6.99,1000.0,113570.0,134771.0,113570.0,0.542337,,0.0,800.0,7.707,,,Greenwood Village,[],United States,USD,6.86,4.15,1638230400.0,6.91,6.735,8.021,,,3.852,3.875,14235000.0,0.16186,4.966,0.804,70697928,1582156800,NGM,America/New_York,EST,,6.7248,8.41,4.6,USD,,,15011390.0,4.34,1.5806451,16085875,,136.0,,,-18000000,0.42668998,21164000.0,0.01933,0.44518003,,Pollution & Treatment Controls,False,,1582156800,0.25,1609372800,,1395014400,2:1,,"Advanced Emissions Solutions, Inc., together with its subsidiaries, provides environmental technologies and specialty chemicals in the United States. It operates through two segments, Refined Coal and Advanced Purification Technologies. The company offers CyClean technology, a pre-combustion coal treatment process to enhance combustion, as well as to reduce emissions of nitrogen oxide and mercury from coals burned in cyclone boilers; and M-45 and M-45-PC technologies, which are pre-combustion coal treatment technologies used to control emissions from circulating fluidized bed boilers and pulverized coal boilers. It also provides mercury and other air contaminants controls; and activated carbon products, such as powdered activated carbon and granular activated carbon, as well as owns an associated lignite mine that supplies the raw material for the powdered activated carbon plant. The company's products are used in removal of heavy metal pollutants; treatment of drinking and waste waters; industrial acid gas and odor removal; automotive gasoline emission control; soil and ground water remediation; and food and beverage process and product purifications. It serves customers in the coal-fired power generation and industrial boiler processes. The company was founded in 1996 and is headquartered in Greenwood Village, Colorado.","Advanced Emissions Solutions, Inc.",us_market,129414592,1.0,,finmb_5013582,,,1632960000,,55014992,1672444800,,6.82,,44239000,0.06083,0,,720 598 3500,6.82,2.0,0.89009994,1.4715568,0.62551,3.49,EQUITY,buy,2,6.91,6.735,6.82,6.82,71954.0,0.01982,0.48816,0.482,4.828,,Industrials,18865100.0,0.0069999998,132126.0,1635465600.0,164889.0,"Advanced Emissions Solutions, I",0.008,0.75,,CO,,ADES,,,,,,,,66139000.0,3.615,11312000.0,87944000.0,False,0.25,0.03665689,2.999,6.4764,71954.0,,,https://www.advancedemissionssolutions.com,,,80111,2.287429,,Suite 210
49,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50,175.77,https://logo.clearbit.com/analog.com,0.19695938,0.29132175,One Analog Way,,,,176.42,1300.0,3072810.0,3210939.0,3072810.0,1.124675,,173.0,900.0,72.321,,,Wilmington,[],United States,USD,175.77,1.941,1639526400.0,176.66,174.595,18.736,2.76,0.015800001,-0.855,-0.804,2848005888.0,0.38916,34.044,13.249,96957562880,1638403200,NMS,America/New_York,EST,,179.6032,191.95,142.25,USD,,1.93,523145296.0,8.51,20.654524,1119481856,,24700.0,,,-18000000,0.61831003,4525012000.0,0.0021799998,0.88198,,Semiconductors,False,,1638403200,0.69,1635552000,,953164800,2:1,,"Analog Devices, Inc. designs, manufactures, tests, and markets integrated circuits (ICs), software, and subsystems that leverage analog, mixed-signal, and digital signal processing technologies. The company provides data converter products, which translate real-world analog signals into digital data, as well as translates digital data into analog signals; power management and reference products for power conversion, driver monitoring, sequencing, and energy management applications in the automotive, communications, industrial, and high-end consumer markets; and power ICs include performance, integration, and software design simulation tools for accurate power supply designs. It also offers high-performance amplifiers to condition analog signals; and radio frequency and microwave ICs to support cellular infrastructure; and microelectromechanical systems technology solutions, including accelerometers used to sense acceleration, gyroscopes for sense rotation, inertial measurement units to sense multiple degrees of freedom, and broadband switches for radio and instrument systems, as well as isolators. In addition, the company offers digital signal processing and system products for high-speed numeric calculations. It serves clients in the industrial, automotive, consumer, instrumentation, aerospace, and communications markets through a direct sales force, third-party distributors, and independent sales representatives in the United States, the rest of North and South America, Europe, Japan, China, and rest of Asia, as well as through its Website. Analog Devices, Inc. was incorporated in 1965 and is headquartered in Wilmington, Massachusetts.","Analog Devices, Inc.",us_market,92337430528,1.0,,finmb_251411,,,1635552000,,1390422016,1698624000,25,174.75,,2735068928,0.24232,0.7775,1.57,781 935 5565,174.78,2.0,2.4304144,12.617358,0.18999,1.241,EQUITY,buy,1.9,176.66,174.595,174.75,174.78,1916236.0,0.03004,0.055630002,0.533,18.413,,Technology,525331008.0,0.0149,7837481.0,1636934400.0,7884010.0,"Analog Devices, Inc.",0.015,2.24,,MA,,ADI,220,180,208.16,210,,,,1977964032.0,3.765,7118233088.0,7318285824.0,False,2.76,0.01579128,3.46,167.59476,1916236.0,,,https://www.analog.com,,,01887,50.80058,,
51,1.41,https://logo.clearbit.com/admabiologics.com,-0.3744076,0.29132175,465 State Route 17,,,,1.41,1100.0,2752610.0,2569742.0,2752610.0,1.233246,,1.4,2200.0,0.743,,,Ramsey,[],United States,USD,1.41,5.405,1639526400.0,1.42,1.31,99.027,,,,,-48892552.0,-0.71359,-6.664,4.756,325843680,,NGM,America/New_York,EST,,1.3618,3.111,1.01,USD,,,181262892.0,-0.24,-5.875,-90136696,,406.0,,,-18000000,0.0001,-11571643.0,0.02794,0.23637,,Biotechnology,False,,,,1609372800,,,,,"ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.","ADMA Biologics, Inc.",us_market,276097728,1.0,,finmb_51119246,,,1632960000,,-74405968,1672444800,6,1.32,,-111123184,-0.78963995,0,,201 478 5552,1.32,4.0,1.897712,4.0296917,-1.08597,1.695,EQUITY,buy,1.7,1.42,1.31,1.32,1.32,2553184.0,-0.15777999,-0.85447,1.012,0.579,,Healthcare,195814000.0,0.0509,9958037.0,1636934400.0,11162777.0,ADMA Biologics Inc,0.057800002,5.34,,NJ,,ADMA,10,3,5.58,5,,,,34410568.0,0.176,101780000.0,68515848.0,False,,,-0.628,1.512525,2553184.0,,,https://www.admabiologics.com,,,07446,,201 478 5553,
52,0.605,https://logo.clearbit.com/adamispharmaceuticals.com,0.07407403,0.29132175,11682 El Camino Real,,,,0.6162,800.0,1415080.0,6066404.0,1415080.0,1.312727,,0.6046,800.0,0.232,,,San Diego,[],United States,USD,0.605,4.556,1639526400.0,0.6517,0.5701,2.25,,,,,-37854116.0,-2.12679,-1.55,3.296,58665816,,NCM,America/New_York,EST,,0.85,2.34,0.49,USD,,,147674208.0,-0.16,-3.7812502,-28986774,,116.0,,,-18000000,0.15084,1633575.0,0.009649999,0.10163,,Drug Manufacturers—Specialty & Generic,False,,,,1609372800,,1386892800,1:17,,"Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.",Adamis Pharmaceuticals Corporation,us_market,90076032,1.0,,finmb_41081420,,,1632960000,,-52203796,1672444800,,0.577,,-36552584,-2.28832,0,,858 997 2400,0.5818,4.0,2.6077588,5.0608163,0,3.896,EQUITY,hold,3,0.6517,0.5701,0.577,0.5818,2847627.0,-0.57211,-1.68765,-0.125,0.137,,Healthcare,148886000.0,0.059899997,8915155.0,1636934400.0,11936800.0,Adamis Pharmaceuticals Corporat,0.0602,3.4,,CA,,ADMP,,,,,,,,28731894.0,0.193,775753.0,17798716.0,False,,,-0.421,0.93885,2847627.0,,,https://www.adamispharmaceuticals.com,,,92130,,,Suite 300
53,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
54,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
55,246.58,https://logo.clearbit.com/adp.com,0.45336175,0.29132175,One ADP Boulevard,,,,246.62,1100.0,1280080.0,1395793.0,1280080.0,0.757402,,246.71,800.0,12.679,,,Roseland,[],United States,USD,246.58,1.048,1639526400.0,247.75,244.59,65.01,4.16,0.016900001,0.179,0.163,4003500032.0,0.26052,26.308,6.854,105322962944,1639008000,NMS,America/New_York,EST,,231.1656,248.96,159.31,USD,,2.01,420692972.0,7.47,33.009373,3333612544,,56000.0,,,-18000000,0.45167,6768100000.0,0.00099,0.80867994,,Staffing & Employment Services,False,,1639008000,1.04,1625011200,,1412121600,1139:1000,,"Automatic Data Processing, Inc. provides cloud-based human capital management solutions worldwide. It operates in two segments, Employer Services and Professional Employer Organization (PEO). The Employer Services segment offers strategic, cloud-based platforms, and human resources (HR) outsourcing solutions. Its offerings include payroll, benefits administration, talent management, HR management, workforce management, insurance, retirement, and compliance services. The PEO Services segment provides HR outsourcing solutions to small and mid-sized businesses through a co-employment model. This segment offers benefits package, protection and compliance, talent engagement, comprehensive outsourcing, and recruitment process outsourcing services. The company was founded in 1949 and is headquartered in Roseland, New Jersey.","Automatic Data Processing, Inc.",us_market,103904870400,1.0,,finmb_126269,,,1632960000,,2696900096,1688083200,17,245.45,,2733299968,0.22742,0.5886,2.61,973 974 5000,245.56,2.0,19.447906,6.7615585,0.17549999,0.089,EQUITY,hold,3,247.75,244.59,245.45,245.56,820313.0,0.04267,0.48333,0.104,36.2,,Industrials,421384000.0,0.0114,4790207.0,1636934400.0,4226756.0,"Automatic Data Processing, Inc.",0.0114,2.9,,NJ,,ADP,260,171,230.61,238,,,,1630599936.0,3.87,3478500096.0,15367000064.0,False,3.72,0.015149048,6.32,207.70555,820313.0,,,https://www.adp.com,,,07068,39.015823,,
56,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
57,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
58,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
59,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
60,281.19,https://logo.clearbit.com/autodesk.com,-0.050970197,0.29132175,111 McInnis Parkway,,,,282.06,900.0,1218160.0,1475815.0,1218160.0,1.400519,,277.0,900.0,5.812,,,San Rafael,[],United States,USD,281.19,0.809,1639526400.0,283.925,280.34,238.261,,,0.034,0.034,784700032.0,0.18621,80.574,15.004,63226109952,1111449600,NMS,America/New_York,EST,,293.9072,344.39,245.05,USD,,,219652256.0,6.83,41.169838,1292612480,,11500.0,,,-18000000,0.91737,3484900000.0,0.00187,0.92959,,Software—Application,False,,1111449600,0.015,1612051200,,1103587200,2:1,,"Autodesk, Inc. provides 3D design, engineering, and entertainment software and services worldwide. The company offers AutoCAD Civil 3D, a surveying, design, analysis, and documentation solution for civil engineering, including land development, transportation, and environmental projects; BIM 360, a construction management cloud-based software; AutoCAD, a software for professional design, drafting, detailing, and visualization; AutoCAD LT, a drafting and detailing software; computer-aided manufacturing (CAM) software for computer numeric control machining, inspection, and modelling for manufacturing; Fusion 360, a 3D CAD, CAM, and computer-aided engineering tool; and Industry Collections tools for professionals in architecture, engineering and construction, product design and manufacturing, and media and entertainment collection industries. It also provides Inventor tools for 3D mechanical design, simulation, analysis, tooling, visualization, and documentation; Vault, a data management software to manage data in one central location, accelerate design processes, and streamline internal/external collaboration; Maya and 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and Shotgun, a cloud-based software for review and production tracking in the media and entertainment industry. In addition, the company offers PlanGrid, a cloud-based field collaboration software, which provides general contractors, subcontractors, owners, and architects access to construction information in real-time; Revit software for building information modeling; and BuildingConnected, a bid-management solution. Autodesk, Inc. sells its products and services to customers directly, as well as through a network of resellers and distributors. The company was founded in 1982 and is headquartered in San Rafael, California.","Autodesk, Inc.",us_market,61854208000,1.0,,finmb_119902,,,1635638400,,1319200000,1675123200,21,281.71,,1466099968,0.16372,0,1.95,415 507 5000,281.71,2.0,48.38094,14.678265,0.31305,0.723,EQUITY,buy,2.1,283.925,280.34,281.71,281.71,605043.0,0.05957,1.9555299,0.182,19.181,,Technology,219972992.0,0.0128,2811456.0,1636934400.0,2405491.0,"Autodesk, Inc.",0.0128,1.23,,CA,,ADSK,440,250,329.81,340,,,,1792099968.0,8.147,3049499904.0,4214000128.0,False,,,5.928,293.02744,605043.0,,,https://www.autodesk.com,,,94903,47.43421,415 507 5100,
61,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
62,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
64,0.1556,https://logo.clearbit.com/advaxis.com,-0.64028776,0.29132175,9 Deer Park Drive,,,,0.0,900.0,5456030.0,4953109.0,5456030.0,2.215064,,0.0,800.0,0.304,,,Monmouth Junction,[],United States,USD,0.1556,7.034,1638230400.0,0.16,0.143,,,,,,-17974000.0,0.0,1.303,-7.226,-23411232,,NCM,America/New_York,EST,,0.38566,1.57,0.121,USD,,,145561271.0,-0.15,-1.0373333,-4016375,,17.0,,,-18000000,1.0,253000.0,0.00065,0.11512,,Biotechnology,False,,,,1604102400,,1553817600,1:15,,"Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.","Advaxis, Inc.",us_market,22661272,1.0,,finmb_7924894,,,1627689600,,-18878000,1667174400,,0.1525,,-14921000,-5.81204,0,,609 452 9813,0.15,4.0,0.51184213,6.99422,0,6.71,EQUITY,buy,2,0.16,0.143,0.1525,0.15,1444533.0,-0.25855,-0.49847,,0.029,,Healthcare,145638000.0,0.0215,3133134.0,1635465600.0,4496565.0,"Advaxis, Inc.",0.0215,0.64,,NJ,,ADXS,,,,,,,,45257000.0,0.311,0.0,3240000.0,False,,,-0.171,0.476975,1444533.0,,,https://www.advaxis.com,,,08852,,609 452 9818,Suite K-1
65,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
66,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
67,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
68,24.18,https://logo.clearbit.com/aehr.com,8.661157,0.29132175,400 Kato Terrace,,,,24.36,800.0,1702010.0,2422015.0,1702010.0,1.396363,,24.12,1200.0,0.581,,,Fremont,[],United States,USD,24.18,2.477,1639526400.0,24.65,23.41,10.982,,,5.358,5.505,-2687000.0,-0.1328,-229.229,30.441,615937152,,NCM,America/New_York,EST,,19.876,27.09,1.94,USD,,,24167726.0,0.69,35.04348,-165750,,79.0,,,-18000000,0.39962003,6032000.0,0.09125,0.29536,,Semiconductor Equipment & Materials,False,,,,1622419200,,,,,"Aehr Test Systems primarily designs, engineers, manufactures, and sells test and burn-in equipment for use in the semiconductor industry in North America, Asia, and Europe. It provides full wafer contact test systems, test during burn-in systems, test fixtures, and related accessories. The company offers Advanced Burn-in and Test System family of packaged part burn-in and test systems, which perform test during burn-in of complex devices, such as digital signal processors, microprocessors, microcontrollers, memory and systems-on-a-chip, as well as individual temperature control for high-power advanced logic devices. It also provides FOX systems that are parallel test and burn-in systems designed to contact devices on wafers or panels of devices simultaneously; WaferPak contactor that includes a full-wafer probe card for use in testing wafers in FOX systems; DiePak carrier, a reusable and temporary package that enables integrated circuit (IC) manufacturers to perform test and burn-in of singulated bare die or very small multi-IC modules; and test fixtures that hold the devices undergoing test or burn-in and electrically connect the devices under test to the system electronics. In addition, the company offers WaferPak Aligner, which performs automatic alignment of the customer's wafer to the WaferPak contactor; and DiePak Loader that performs automatic loading of the customer's modules to the DiePak carrier. Further, Aehr Test Systems provides customer service and support programs, including system installation, system repair, applications engineering support, spare parts inventory, customer training, and documentation services. The company markets and sells its products to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers, and burn-in and test service companies through a network of distributors and sales representatives. Aehr Test Systems was incorporated in 1977 and is headquartered in Fremont, California.",Aehr Test Systems,us_market,642150656,1.0,,finmb_24413,,,1630368000,,-1438000,1685491200,1,23.51,,-1470000,-0.14767,0,2.64,510 623 9400,23.38,2.0,41.617905,31.73622,-0.07107,1.232,EQUITY,none,,24.65,23.41,23.51,23.38,921880.0,-0.08748999,-0.10831001,1.806,0.856,,Technology,26557100.0,0.0499,1324787.0,1636934400.0,1237124.0,Aehr Test Systems,0.0563,0.99,,CA,,AEHR,31,31,31,31,,,,6530000.0,0.246,1563000.0,20234000.0,False,,,-0.062,9.3059,921880.0,,,https://www.aehr.com,,,94539,,510 623 9450,
69,90.41,https://logo.clearbit.com/advancedenergy.com,-0.0679152,0.28379917,1595 Wynkoop Street,,,,0.0,800.0,299200.0,216398.0,299200.0,1.694545,,0.0,1000.0,22.258,,,Denver,[],United States,USD,90.41,3.006,1639526400.0,90.95,89.48,60.593,0.4,0.0044,-0.535,-0.54,233874000.0,0.16354999,14.391,2.354,3365697792,1637280000,NMS,America/New_York,EST,,89.248,125.55,81.71,USD,,,37186334.0,5.15,17.55534,126516624,,10000.0,,,-18000000,0.38282,551599000.0,0.01274,1.01433,,Electrical Equipment & Parts,False,,1637280000,0.1,1609372800,,,,,"Advanced Energy Industries, Inc. designs, manufactures, sells, and supports precision power conversion, measurement, and control solutions worldwide. It offers process power solutions, including direct current (DC), pulsed DC, low frequency alternating current, high voltage, and radio frequency (RF) power supplies, as well as RF matching networks and remote plasma sources for reactive gas applications and RF instrumentation. The company also provides power control modules and thermal instrumentation products for rapid thermal processing, chemical vapor deposition, crystal growing, and other semiconductor and adjacent thin film applications, as well as in chemical processing, metal and glass manufacturing, and other general industrial power applications; high voltage DC-DC products for semiconductor wafer processing and metrology, electrostatic clamping of substrates, scientific instrumentation, mass spectrometry, and analytical X-ray systems for industrial and analytical applications; and low voltage DC-DC board mounted solutions for use in healthcare, telecommunications, test and measurement, instrumentation, and industrial equipment applications, as well as distributed power in server and storage systems. In addition, it offers gas detection and monitoring products for the automotive, energy, environmental control, aerospace, medical, and research industries; and embedded power products for medical equipment or IEC 60950-1 for information technology equipment. Further, it offers conversions, upgrades, and refurbishments and used equipment to companies, as well as repair services. The company provides its products through a direct sales force, independent sales representatives, channel partners, and distributors. Advanced Energy Industries, Inc. was incorporated in 1981 and is headquartered in Denver, Colorado.","Advanced Energy Industries, Inc.",us_market,3405708800,1.0,,finmb_343596,,,1632960000,,136751008,1672444800,9,90.74,,172750000,0.12749,0.0845,2.04,970 407 4670,90.58,2.0,4.0619106,2.3816264,0.09575,2.039,EQUITY,buy,2.5,90.95,89.48,90.74,90.58,121070.0,0.06559,0.16993,-0.111,37.342,,Industrials,37669600.0,0.0221,833139.0,1636934400.0,743006.0,"Advanced Energy Industries, Inc",0.030299999,3.7,,CO,,AEIS,120,87,106.56,112,,,,550755968.0,14.621,510071008.0,1429992960.0,False,0.3,0.0033119894,3.554,96.83395,121070.0,,,https://www.advancedenergy.com,,,80202,25.438944,970 407 6296,Suite 800
70,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
71,7.15,https://logo.clearbit.com/aeriepharma.com,-0.46431202,0.2825023,4301 Emperor Boulevard,,,,7.54,1100.0,1469010.0,1060333.0,1469010.0,0.852987,,7.0,1000.0,-1.545,,,Durham,[],United States,USD,7.15,2.336,1639526400.0,7.36,7.04,,,,,,-96999000.0,-0.93133,-4.466,4.159,433196448,,NGM,America/New_York,EST,,10.2372,21.3,7.04,USD,,,42984999.0,-1.89,-3.783069,-35424876,,365.0,,,-18000000,0.73778,55501000.0,0.03023,1.0689601,,Drug Manufacturers—Specialty & Generic,False,,,,1609372800,,,,,"Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.","Aerie Pharmaceuticals, Inc.",us_market,338606144,1.0,,finmb_24309870,,,1632960000,,-166480000,1672444800,8,7.19,,-46682000,-1.28359,0,0.05,919 237 5300,7.28,2.0,,3.251108,-1.5984501,1.965,EQUITY,buy,2,7.36,7.04,7.19,7.28,982001.0,-0.23257999,,0.46,2.256,,Healthcare,47357500.0,0.0946,4479373.0,1636934400.0,4273780.0,"Aerie Pharmaceuticals, Inc.",0.0968,3.12,,NC,,AERI,30,9,23.13,24,,,,167607008.0,3.539,254620000.0,104151000.0,False,,,-3.607,14.450525,982001.0,,,https://www.aeriepharma.com,,,27703,,,Suite 400
72,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
73,1.69,https://logo.clearbit.com/addvantagetechnologies.com,-0.39649123,0.29132175,1430 Bradley Lane,,,,1.7,1800.0,1626370.0,285731.0,1626370.0,,,1.68,4000.0,0.827,,,Carrollton,[],United States,USD,1.69,1.487,1639526400.0,1.72,1.61,70.969,,,,,-8092000.0,-0.13018,-3.273,0.426,26481594,,NGM,America/New_York,EST,,1.9818,3.59,1.61,USD,,,6770306.0,,,-4172750,,,,,-18000000,0.25944,16127000.0,0.37787998,0.03686,,Electronics & Computer Distribution,False,,,,1632960000,,907891200,1:4,,"ADDvantage Technologies Group, Inc., through its subsidiaries, distributes and services electronics and hardware for the telecommunications industry in the United States and internationally. It operates through two segments, Wireless Infrastructure Services and Telecommunications. The Wireless Infrastructure Services segment provides turn-key wireless infrastructure services for U.S. wireless carriers, communication tower companies, national integrators, and original equipment manufacturers. This segment also offers installation and upgradation of technology on cell sites; and the construction of new small cells for 5G. The Telecommunications segment provides central office equipment that include optical transport, switching, and data center equipment for communication networks; customer premise equipment, such as integrated access devices, channel banks, Internet protocol private branch exchange phones, and routers; and decommissioning services for surplus and obsolete telecom equipment. The company was formerly known as ADDvantage Media Group, Inc. and changed its name to ADDvantage Technologies Group, Inc. in December 1999. ADDvantage Technologies Group, Inc. was incorporated in 1989 and is headquartered in Carrollton, Texas.","ADDvantage Technologies Group, Inc.",us_market,21530094,1.0,,finmb_410202,,,1632960000,,-6502000,1696032000,,1.7,,-7510000,-0.14994,0,,918 251 9121,1.72,4.0,2.043531,0.34636572,-0.1046,0.909,EQUITY,none,,1.72,1.61,1.7,1.72,299620.0,-0.19418,-0.51278,0.612,5.012,,Technology,12739700.0,0.0094,119147.0,1636934400.0,116271.0,"ADDvantage Technologies Group, ",0.0149,3.53,,TX,,AEY,,,,,,,,2608000.0,0.207,7400000.0,62160000.0,False,,,-0.524,2.3026,299620.0,,,https://www.addvantagetechnologies.com,,,75007,,,Suite 196
74,0.3553,https://logo.clearbit.com/zentaris.com,-0.2745098,0.29132175,315 Sigma Drive,,,,0.355,2200.0,1270850.0,1998398.0,1270850.0,2.070603,,0.3502,1000.0,0.494,,,Summerville,[],United States,USD,0.3553,15.156,1639526400.0,0.38,0.35,0.334,,,,,-6551000.0,-1.57741,3.538,-5.581,-23176460,,NCM,America/New_York,EST,,0.5016,3.62,0.35,USD,,,121248903.0,-0.11,-3.23,-3244625,,12.0,,,-18000000,0.64315003,1335000.0,0.00071999995,0.03995,,Biotechnology,False,,,,1609372800,,1447977600,1:100,,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.",Aeterna Zentaris Inc.,us_market,43595668,1.0,,finmb_416430,,,1632960000,,-6493000,1672444800,1,0.3785,,-3650000,-1.56441,0,,843 900 3223,0.3676,4.0,0.71923083,10.497392,-1.56345,14.426,EQUITY,none,,0.38,0.35,0.3785,0.3676,2854175.0,-0.071040004,-0.17297001,3.703,0.041,,Healthcare,121397000.0,0.0298,3614132.0,1636934400.0,3588133.0,Aeterna Zentaris Inc.,0.0298,3.18,,SC,,AEZS,2,2,2,2,,,,68002000.0,0.56,200000.0,4153000.0,False,,,-0.068,0.7536,2854175.0,,,https://www.zentaris.com,,,29486,,,
75,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
76,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
77,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
79,5.51,https://logo.clearbit.com/affimed.com,-0.066777945,0.2825023,Technologiepark,,,,5.52,1000.0,966460.0,1810490.0,966460.0,2.575064,,5.51,900.0,1.117,,,Heidelberg,[],Germany,USD,5.51,3.066,1639526400.0,5.6,5.47,8.328,,,,,-49960000.0,-1.22298,-9.649,11.801,482071168,,NGM,America/New_York,EST,,6.2846,11.74,4.78,EUR,,,116568631.0,-0.59,-9.338984,-1426750,,153.0,,,-18000000,1.0,28857000.0,0.027709998,0.64624,,Biotechnology,False,,,,1609372800,,,,,"Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.",Affimed N.V.,us_market,660081472,1.0,,finmb_849883,,,1632960000,,-49308000,1672444800,7,5.57,,-43227000,-1.23894,0,,49 6221 6743 60,5.59,2.0,4.932856,16.15827,-1.20702,3.046,EQUITY,buy,1.6,5.6,5.47,5.57,5.59,459043.0,-0.19272,-0.54522,-0.165,0.365,,Healthcare,119797000.0,0.029000001,3471524.0,1636934400.0,2870132.0,Affimed N.V.,0.0298,1.23,,,,AFMD,18,10.99,13.35,12,,,,198742000.0,1.659,11147000.0,40851000.0,False,,,-0.499,7.3521,459043.0,,,https://www.affimed.com,,,69120,,49 6221 6743 649,Im Neuenheimer Feld 582
80,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
81,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
82,3.22,https://logo.clearbit.com/agenusbio.com,0.043343663,0.29132175,3 Forbes Road,,,,3.21,1800.0,5557230.0,4415171.0,5557230.0,1.134545,,3.21,21500.0,0.169,,,Lexington,[],United States,USD,3.22,2.054,1639526400.0,3.415,3.2,153.562,,,,,75137000.0,0.24500999,8.681,2.127,652288576,,NCM,America/New_York,EST,,3.654,6.79,2.5,USD,,,227177452.0,-0.95,-3.3894737,-31354624,,359.0,,,-18000000,0.46495,-56796000.0,0.11642,0.47994998,,Biotechnology,False,,,,1609372800,,1317600000,1:6,,"Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFÃ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",Agenus Inc.,us_market,826995840,1.0,,finmb_409956,,,1632960000,,3768000,1672444800,3,3.36,,-2518000,0.22228001,0,,781 674 4400,3.37,4.0,19.053255,2.696714,0.0129700005,1.887,EQUITY,buy,1.7,3.415,3.2,3.36,3.37,3594912.0,0.13270001,,16.055,1.44,,Healthcare,256831008.0,0.0727,18674365.0,1636934400.0,15263724.0,Agenus Inc.,0.0733,4.37,,MA,,AGEN,12,7,10,11,,,,261528000.0,1.018,54596000.0,306668000.0,False,,,0.018,4.4599,3594912.0,,,https://agenusbio.com,,,02421-7305,178.8889,781 674 4200,
83,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
85,33.83,https://logo.clearbit.com/agios.com,-0.20295638,0.2505386,88 Sidney Street,,,,33.7,1000.0,1126110.0,538730.0,1126110.0,1.51948,,33.64,1100.0,25.491,,,Cambridge,[],United States,USD,33.83,22.545,1638230400.0,33.88,31.985,7.108,,,,,-329336000.0,-1.62078,-2.058,3.336,677936832,,NMS,America/New_York,EST,,40.8908,62.16,29.21,USD,,,53593774.0,-5.86,-5.773038,-137810496,,562.0,,,-18000000,-0.93193,-167079000.0,0.01184,1.13754,,Biotechnology,False,,,,1609372800,,,,,"Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.","Agios Pharmaceuticals, Inc.",us_market,1837256704,1.0,,finmb_46539787,,,1632960000,,-340532000,1672444800,8,33.23,,-372624000,-1.66911,0,0.03,617 649 8600,33.97,2.0,1.3271352,9.041796,7.8824596,21.989,EQUITY,buy,2.4,33.88,31.985,33.23,33.97,325549.0,-0.17304,-0.36319,,3.165,,Healthcare,54308500.0,0.1364,7409918.0,1635465600.0,7041294.0,"Agios Pharmaceuticals, Inc.",0.2385,15.67,,MA,,AGIO,95,37,59.88,59,,,,1266056960.0,23.312,99135000.0,203196000.0,False,,,24.95,48.90735,325549.0,,,https://www.agios.com,,,02139-4169,1.3559119,,2nd Floor
86,15.04,https://logo.clearbit.com/agnc.com,-0.011695921,0.29132175,2 Bethesda Metro Center,,,,15.05,1800.0,6781270.0,6335711.0,6781270.0,1.021298,,15.06,1800.0,17.508,,,Bethesda,[],United States,USD,15.04,0.202,1639526400.0,15.23,15.02,438.655,1.44,0.0947,-0.696,-0.68,,0.0,,27.565,45316857856,1640822400,NMS,America/New_York,EST,,15.7834,18.84,14.42,USD,,11.34,520399419.0,2.52,5.968254,,,50.0,,,-18000000,1.0,-27000000.0,0.00392,0.51525,,REIT—Mortgage,False,,1640822400,0.12,1609372800,,,,,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",AGNC Investment Corp.,us_market,7894616064,1.0,,finmb_41018622,,,1632960000,,1451000064,1672444800,13,15.105,,1574000000,0.94343,0.5393,1.73,301 968 9315,15.21,2.0,0.8590359,4.802078,0.94343,0.194,EQUITY,buy,2.3,15.23,15.02,15.105,15.21,6301382.0,0.02085,0.14496,-0.657,3.084,,Real Estate,524908000.0,0.03,15747595.0,1636934400.0,14024506.0,AGNC Investment Corp.,0.0301,2.22,,MD,,AGNC,18,15.5,16.83,16.5,,,,11000000512.0,20.956,46843998208.0,1644000000.0,False,1.44,0.09467456,2.713,16.6111,6301382.0,,,https://www.agnc.com,,,20814,5.5436783,301 968 9301,12th Floor
87,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
88,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
89,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
90,0.4881,https://logo.clearbit.com/agiletherapeutics.com,-0.8240143,0.29132175,101 Poor Farm Road,,,,0.4876,1400.0,1489100.0,2295268.0,1489100.0,0.993766,,0.4886,900.0,0.113,,,Princeton,[],United States,USD,0.4881,2.274,1639526400.0,0.4998,0.4702,154.223,,,,,-63611000,0.0,-0.964,18.373,61292892,,NCM,America/New_York,EST,,0.67146,3.77,0.4702,USD,,,98527448.0,-0.39,-1.2515385,-41816752,,28.0,,,-18000000,-0.58843,467000.0,0.01039,0.34605,,Drug Manufacturers—Specialty & Generic,False,,,,1609372800,,,,,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.","Agile Therapeutics, Inc.",us_market,59253388,1.0,,finmb_858721,,,1632960000,,-69157000,1672444800,3,0.4702,,-65926000,-19.60072,0,,609 683 1880,0.4906,4.0,4.319469,17.761806,0,1.677,EQUITY,buy,1.7,0.4998,0.4702,0.4702,0.4906,1363231.0,-0.64821,-1.80073,,0.037,,Healthcare,121396000.0,0.0199,2411846.0,1636934400.0,1443107.0,"Agile Therapeutics, Inc.",0.024600001,1.24,,NJ,,AGRX,4,2,2.83,2.5,,,,14735000.0,0.121,16471000.0,3336000.0,False,,,-0.774,1.20598,1363231.0,,,https://www.agiletherapeutics.com,,,08540,,,
91,1.9,https://logo.clearbit.com/agtc.com,-0.5437788,0.29132175,14193 NW 119th Terrace,,,,1.92,2200.0,556020.0,636509.0,556020.0,1.934025,,1.91,1300.0,1.622,,,Alachua,[],United States,USD,1.9,4.302,1639526400.0,2.0384,1.9,35.156,,,,,-58371000,0.0,-0.322,37.594,18796832,,NGM,America/New_York,EST,,2.3296,9.67,1.84,USD,,,38753795.0,-1.35,-1.4074074,-32141624,,83.0,,,-18000000,0.0,-22583000.0,0.00537,0.44672,,Biotechnology,False,,,,1625011200,,,,,"Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.",Applied Genetic Technologies Corporation,us_market,81440840,1.0,,finmb_7604030,,,1632960000,,-59568000,1688083200,8,1.97,,-54192000,-119.628,0,,386 462 2204,1.98,4.0,1.1713934,162.88168,0,4.169,EQUITY,buy,1.7,2.0384,1.9,1.97,1.98,551968.0,-0.38142,-0.94758004,,0.014,,Healthcare,42863600.0,0.0476,2038724.0,1636934400.0,2248345.0,Applied Genetic Technologies Co,0.0477,2.27,,FL,,AGTC,35,8,16,12,,,,90515000.0,2.112,24442000.0,500000.0,False,,,-1.611,3.46935,551968.0,,,https://agtc.com,,,32615,,,Suite 10
92,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
93,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
94,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
95,6.0,https://logo.clearbit.com/alliedhpi.com,0.22176588,0.27608383,1720 Sublette Avenue,,,,6.0,1200.0,1398230.0,1593540.0,1398230.0,-5.08,,5.95,1200.0,2.392,,,Saint Louis,[],United States,USD,6.0,1.731,1639526400.0,6.1,5.7,24.086,,,,,-816254,-0.024400001,-31.769,0.775,25931206,835747200,NCM,America/New_York,EST,,5.601,16.41,3.45,USD,,,3513611.0,,,-186258,,189.0,,,-18000000,0.18455,7109496.0,0.18821,0.047670003,,Medical Devices,False,,835747200,0.14,1625011200,,1481068800,1:2,,"Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products comprising aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, portable suction equipment, and a line of respiratory disposable products. It also provides medical gas equipment, which include construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers emergency medical products that include respiratory/resuscitation products, such as demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products that include spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. It serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. The company was incorporated in 1979 and is headquartered in St. Louis, Missouri.","Allied Healthcare Products, Inc.",us_market,24081240,1.0,,finmb_24618,,,1632960000,,856563,1688083200,,5.85,,-840216,-0.040170003,0,,314 771 2400,5.95,2.0,2.5083613,0.7199709,0.025610002,0.454,EQUITY,none,,6.1,5.7,5.85,5.95,280551.0,-0.045679998,0.09348,-0.278,8.334,,Healthcare,4013540.0,0.0402,161403.0,1636934400.0,97022.0,"Allied Healthcare Products, Inc",0.0436,0.04,,MO,,AHPI,,,,,,,,261806.0,0.065,2312467.0,33447520.0,False,,,0.211,5.87135,280551.0,,,https://www.alliedhpi.com,,,63110,28.43602,,
96,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
97,12.96,https://logo.clearbit.com/apolloic.com,0.2292453,0.26514983,9 West 57th Street,,,,12.97,800.0,817370.0,378270.0,817370.0,2.026493,,12.95,1100.0,16.07,,,New York,[],United States,USD,12.96,1.302,1638230400.0,13.071,12.87,153.762,1.24,0.0952,-0.233,-0.236,,0.0,,11.546,2408815104,1639699200,NGM,America/New_York,EST,,13.1318,15.27,10.4,USD,,12.16,,1.39,9.323741,66585248,,,,,-18000000,1.0,216749000.0,0.00602,0.32834,,Asset Management,False,,1639699200,0.36,1617148800,,1543795200,1:3,,"Apollo Investment Corporation is business development company specializing in middle market companies. It provides direct equity capital, mezzanine and senior secured loans, unsecured debt, and subordinated debt and loans. It also seeks to invest in PIPES transactions. The fund may also invest in securities of public companies that are thinly traded and may acquire investments in the secondary market and structured products. It prefers to invest in warrants, makes equity co-investments, and may also invest in cash equivalents, U.S. government securities, high-quality debt investments that mature in one year or less, high-yield bonds, distressed debt, non-U.S. investments, or securities of public companies that are not thinly traded. It also focuses on other investments such as collateralized loan obligations and credit-linked notes. The fund typically invests in building materials, business services, cable television, chemicals, consumer products, direct marketing, distribution, energy and utilities, financial services, healthcare, manufacturing, media, publishing, retail and transportation. It primarily invests between $20 million and $250 million in its portfolio companies. The fund seeks to make investments with stated maturities of five to 10 years.",Apollo Investment Corporation,us_market,834035648,1.0,,finmb_9589328,,,1632960000,,133162000,1680220800,9,13.03,,111828000,0.73456,0.6108,3.12,212-515-3200,13.03,2.0,0.8064717,3.9976592,0.63827,1.273,EQUITY,hold,3,13.071,12.87,13.03,13.03,82053.0,0.03585,0.13011,-0.036,3.2,,Financial Services,64354600.0,0.0232,1495507.0,1635465600.0,2010223.0,Apollo Investment Corporation -,0.024400001,4.18,,NY,,AINV,16,12,13.86,13.5,,,,27518000.0,0.428,1597792000.0,208631008.0,False,1.29,0.0990023,2.043,13.7289,82053.0,,,https://www.apolloic.com,,,10019,6.343612,212-515-3251,43rd Floor
98,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
101,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
102,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
103,117.04,https://logo.clearbit.com/akamai.com,0.11316991,0.29132175,145 Broadway,,,,117.1,900.0,1111730.0,1318188.0,1111730.0,0.53974,,115.63,1300.0,28.213,,,Cambridge,[],United States,USD,117.04,3.776,1639526400.0,117.435,116.415,62.094,,,0.137,0.128,1133944064,0.33330002,17.605,5.868,19962648576,,NMS,America/New_York,EST,,111.3708,124.91,92.64,USD,,,159878613,5.93,19.73693,606096512,,8411.0,,,-18000000,0.63335,2065477000.0,0.01564,0.93289,,Software—Infrastructure,False,,,,1609372800,,,,,"Akamai Technologies, Inc. provides cloud services for securing, delivering, and optimizing content and business applications over the internet in the United States and internationally. The company offers cloud and enterprise security solutions to keep infrastructure, websites, applications, application programming interfaces, and users safe from various cyberattacks and online threats while enhancing performance. It also provides web and mobile performance solutions to enable dynamic websites and applications; media delivery solutions, including video streaming and video player services, game and software delivery, broadcast operations, authoritative domain name system, resolution, and data and analytics; and edge compute solutions to enable developers to deploy and distribute code at the edge. In addition, the company offers carrier offerings, including cyberthreat protection, parental controls, DNS infrastructure and content delivery solutions; and an array of service and support to assist customers with integrating, configuring, optimizing, and managing its offerings. It sells its solutions through direct sales and service organizations, as well as through various channel partners. Akamai Technologies, Inc. has a strategic partnership with Queue-It to deliver a cure for Covid vaccine registration. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.","Akamai Technologies, Inc.",us_market,19016658944,1.0,,finmb_24522,,,1632960000,,604478016,1672444800,13,117.04,,1308755968,0.22331,0,1.74,617-444-3000,117.15,2.0,4.1484423,5.589597,0.17767,3.524,EQUITY,buy,2.3,117.435,116.415,117.04,117.15,717377.0,0.060760003,0.13912,0.085,20.882,,Technology,162480000.0,0.0728,11831762.0,1636934400.0,9524854.0,"Akamai Technologies, Inc.",0.0832,8.81,,MA,,AKAM,183,120,135.31,130,,,,1917284992.0,11.8,2845411072.0,3402151936.0,False,,,3.641,111.3282,717377.0,,,https://www.akamai.com,,,02142,32.145016,617-444-3001,
104,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
105,2.26,https://logo.clearbit.com/akebia.com,-0.217094,0.29132175,245 First Street,,,,2.28,21500.0,4267900.0,2660893.0,4267900.0,1.56935,,2.24,4000.0,0.786,,,Cambridge,[],United States,USD,2.26,1.745,1639526400.0,2.35,2.24,89.836,,,,,-189442000,-0.89922994,-1.672,1.503,316665344,,NGM,America/New_York,EST,,2.7044,5.14,2.2,USD,,,173268546,-0.77,-2.935065,-85554496,,379.0,,,-18000000,-0.10346,12859000.0,0.0104,0.59677,,Biotechnology,False,,,,1609372800,,,,,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","Akebia Therapeutics, Inc.",us_market,395409600,1.0,,finmb_36644983,,,1632960000,,-299161984,1672444800,6,2.29,,-220939008,-1.07125,0,,617 871 2098,2.29,4.0,2.875318,1.8768967,-1.42004,1.376,EQUITY,buy,2.1,2.35,2.24,2.29,2.29,3535506.0,-0.22067,-1.31467,-0.187,1.329,,Healthcare,174960000.0,0.0678,11853560.0,1636934400.0,10321801.0,"Akebia Therapeutics, Inc.",0.078600004,3.95,,MA,,AKBA,10,6,7.17,6.5,,,,207204000.0,1.184,123210000.0,210672000.0,False,,,-1.887,2.998175,3535506.0,,,https://www.akebia.com,,,02142,,617 871 2099,Suite 1400
106,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
107,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
108,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
110,4.06,https://logo.clearbit.com/aldeyra.com,-0.38591117,0.29519403,131 Hartwell Avenue,,,,4.14,2200.0,3324760.0,1053590.0,3324760.0,1.664415,,4.05,900.0,3.784,,,Lexington,[],United States,USD,4.06,20.664,1639526400.0,4.2269,3.94,7.205,,,,,-50307204,0.0,-2.632,,132408312,,NCM,America/New_York,EST,,7.5352,15.95,3.37,USD,,,47379921,-1.31,-3.0992367,-130625424,,11.0,,,-18000000,0.0,,0.01461,0.71402,,Biotechnology,False,,,,1609372800,,,,,"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.","Aldeyra Therapeutics, Inc.",us_market,235853920,1.0,,finmb_47399863,,,1632960000,,-53313908,1672444800,10,4.05,,-39295404,0.0,0,-0.05,781 761 4904,4.01,4.0,1.0729387,,0,9.744,EQUITY,strong_buy,1.5,4.2269,3.94,4.05,4.01,1126982.0,-0.18756,-0.36916,,,,Healthcare,58092100.0,0.0581,3377345.0,1636934400.0,3476293.0,"Aldeyra Therapeutics, Inc.",0.0695,4.85,,MA,,ALDX,30,10,20.4,19,,,,116368688.0,2.003,15827661.0,,False,,,-1.084,9.757525,1126982.0,,,https://www.aldeyra.com,,,02421,,339 674 6495,Suite 320
111,657.18,https://logo.clearbit.com/aligntech.com,0.2578733,0.29132175,410 North Scottsdale Road,,,,699.0,2200.0,471600.0,613161.0,471600.0,1.571948,,600.0,1200.0,44.6,,,Tempe,[],United States,USD,657.18,1.371,1639526400.0,674.89,655.62,2.745,,,0.295,0.298,1072601984,0.28557,47.62,13.599,51076780032,,NMS,America/New_York,EST,,647.032,737.45,494.45,USD,,,73876652,13.44,48.897324,781198528,,21590.0,,,-18000000,0.74581003,1763235000,0.06697,0.87566,,Medical Devices,False,,,,1609372800,,,,,"Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.","Align Technology, Inc.",us_market,51820683264,1.0,,finmb_24568,,,1632960000,,740046976,1672444800,11,659.47,,1281112960,0.2579,0,1.37,408 470 1000,662.22,2.0,14.734978,13.796755,0.19703,1.169,EQUITY,buy,2,674.89,655.62,659.47,662.22,462538.0,0.120299995,0.22596,0.384,47.58,,Healthcare,78853104.0,0.0139,1097358.0,1636934400.0,1554127.0,"Align Technology, Inc.",0.0139999995,2.13,,AZ,,ALGN,850,550,752.91,750,,,,1237821952.0,15.698,96522000.0,3756005120,False,,,9.278,632.3272,462538.0,,,https://www.aligntech.com,,,85281,70.83208,408 470 1010,Suite 1300
112,188.2,https://logo.clearbit.com/allegiantair.com,0.04453981,0.25995052,1201 North Town Center Drive,,,,190.0,900.0,269650.0,172444.0,269650.0,1.596363,,188.31,1100.0,66.991,,,Las Vegas,[],United States,USD,188.2,1.906,1638230400.0,189.2593,185.73,142.911,,,,,161452000,0.110769995,24.594,2.724,3970720768,1582848000,NMS,America/New_York,EST,,183.539,271.29,163.6,USD,,,15038193,12.43,15.140788,-75396872,,4261.0,,,-18000000,0.19479999,121327000,0.15392,0.88041997,,Airlines,False,,1582848000,0.7,1609372800,,,,,"Allegiant Travel Company, a leisure travel company, provides travel services and products to residents of under-served cities in the United States. The company offers scheduled air transportation on limited-frequency, nonstop flights between under-served cities and leisure destinations. As of February 12, 2021, it operated a fleet of 97 Airbus A320 series aircraft. The company also provides air-related services and products in conjunction with air transportation, including convenience and baggage fees, advance seat assignments, travel protection products, priority boarding, food and beverage purchases on board, and other air-related services, as well as use of its call center for purchases. In addition, it offers third party travel products, such as hotel rooms and ground transportation, such as rental cars and hotel shuttle products; and air transportation services through fixed fee agreements and charter service on a year-round and ad-hoc basis. Further, the company operates a golf course. Allegiant Travel Company was founded in 1997 and is headquartered in Las Vegas, Nevada.",Allegiant Travel Company,us_market,3404104960,1.0,,finmb_666631,,,1632960000,,110284000,1672444800,11,187.65,,331492000,0.02091,0,0.7,702 851 7300,187.38,2.0,2.8093326,2.3354387,0.07705,1.759,EQUITY,buy,2,189.2593,185.73,187.65,187.38,158965.0,0.00545,0.11805,1.286,86.859,,Industrials,18087700.0,0.026300002,476495.0,1635465600.0,465228.0,Allegiant Travel Company,0.0357,3.22,,NV,,ALGT,305,225,256.09,247,,,,1070971008.0,60.092,1702168064.0,1457586944,False,0,0,6.572,204.82085,158965.0,,,https://www.allegiantair.com,,,89144,28.63664,,
113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
114,23.71,https://logo.clearbit.com/alkermes.com,0.07155967,0.2505386,Connaught House,,,,23.67,1100.0,1132340.0,1193792.0,1132340.0,0.977142,,23.63,1100.0,6.78,,,Dublin,[],Ireland,USD,23.71,2.325,1638230400.0,23.74,22.77,38.301,,,,,15440000,0.01367,235.556,3.221,3636982272,,NMS,America/New_York,EST,,26.2926,33.0,18.02,USD,,,146611788,0.42,56.45238,135208752,,2245.0,,,-18000000,0.83474,860440000,0.011109999,0.97029996,,Biotechnology,False,,,,1609372800,,958348800,2:1,,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.",Alkermes plc,us_market,3834025216,1.0,,finmb_24572,,,1632960000,,-91684000,1672444800,9,23.28,,138036992,-0.05526,0,0.31,353 1 772 8000,23.36,2.0,3.4970498,3.395097,-0.081190005,1.883,EQUITY,hold,2.8,23.74,22.77,23.28,23.36,620561.0,-0.02014,-0.08409,0.11,7.046,,Healthcare,161704992.0,0.070300005,11365284.0,1635465600.0,12098777.0,Alkermes plc,0.0979,8.49,,,,ALKS,33,22,27.22,27,,,,560300032.0,3.465,419844992.0,1129282944,False,,,-0.572,25.1547,620561.0,,,https://www.alkermes.com,,,4,,,1 Burlington Road
115,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
116,11.83,https://logo.clearbit.com/allot.com,0.12737644,0.27429736,22 Hanagar Street,,,,11.84,1200.0,397920.0,223965.0,397920.0,0.683116,,11.83,800.0,3.501,,,Hod HaSharon,[],Israel,USD,11.83,2.746,1639526400.0,11.95,11.7,1.985,,,,,-5771000,-0.040159997,-58.132,2.334,335482144,,NMS,America/New_York,EST,,12.7682,21.04,10.26,USD,,,27821536,-0.79,-14.974683,-12294250,,735.0,,,-18000000,0.69618,95840000,0.02148,0.76194,,Software—Infrastructure,False,,,,1609372800,,,,,"Allot Ltd. provides network intelligence and security solutions to protect and personalize the digital experience in Europe, Asia, Oceania, the Middle East, Africa, and the Americas. It offers Allot Service Gateway (Allot SG) platforms, including Allot SG-Tera, Allot SG9x000, and Allot SG-VE and CE for in-line deployment in traditional and virtualized network access infrastructure. The company also provides subscriber management platform that drives the centralized creation, provisioning, and pricing of subscriber services; and analytics solutions comprising Allot ClearSee Analytics and Allot ClearSee Data Source that analyze traffic data. In addition, it offers security solutions comprising Allot NetworkSecure, Allot HomeSecure, Allot DNSecure, EndPoint Secure, Allot Content Protector, Allot IoTSecure, Allot DDoS Secure, Allot SpamOut Protector, and Allot Secure Management, as well as security as a service solutions for protecting network service integrity and brand reputation. Further, the company offers centralized management solutions, such as Allot NetXplorer for providing a central access point for network-wide monitoring, reporting, analytics, troubleshooting, accounting, and quality of service policy provisioning. It markets its products through direct sales, distributors, resellers, original equipment manufacturers, and system integrators to carriers, mobile and fixed service providers, cable operators, private networks, data centers, educational institutions, governments, and enterprises, as well as wireless, wireline, and satellite Internet service providers. The company was formerly known as Allot Communications Ltd. and changed its name to Allot Ltd. in October 2018. Allot Ltd. was incorporated in 1996 and is based in Hod-Hasharon, Israel.",Allot Ltd.,us_market,430679424,1.0,,finmb_24624,,,1632960000,,-12691000,1672444800,1,11.89,,-3647000,-0.07689,0,,972 9 761 9200,11.86,2.0,3.3790345,2.996719,-0.08831,2.551,EQUITY,none,,11.95,11.7,11.89,11.86,70418.0,-0.0343,-0.09911,0.098,4.017,,Technology,36405700.0,0.0107,387740.0,1636934400.0,422169.0,Allot Ltd.,0.013200001,2.26,,,,ALLT,19.17,19.17,19.17,19.17,,,,97397000.0,2.684,2522000.0,143716992,False,,,-0.361,16.16345,70418.0,,,https://www.allot.com,,,4501317,,972 9 762 8419,Neve Neâeman Industrial Zone B
117,169.58,https://logo.clearbit.com/alnylam.com,0.33512878,0.29132175,675 West Kendall Street,,,,173.0,900.0,1284800.0,738896.0,1284800.0,0.898701,,163.0,1000.0,6.327,,,Cambridge,[],United States,USD,169.58,4.381,1639526400.0,175.32,169.58,100.602,,,,,-661734976,-0.88311994,-28.543,25.207,18887964672,,NMS,America/New_York,EST,,181.8276,212.0,124.0,USD,,,118891942,-3.92,-43.260204,136807120,,1453.0,,,-18000000,0.83251,414801000,0.00587,0.94782996,,Biotechnology,False,,,,1609372800,,,,,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","Alnylam Pharmaceuticals, Inc.",us_market,20281937920,1.0,,finmb_2796659,,,1632960000,,-837904000,1672444800,20,171.62,,-614696000,-0.94528,0,-3.3,617 551 8200,171.03,2.0,26.802591,27.067343,-1.11823,4.043,EQUITY,buy,2.2,175.32,169.58,171.62,171.03,374701.0,-0.1306,-0.85027003,0.491,6.373,,Healthcare,119601000.0,0.031400003,3755339.0,1636934400.0,4048537.0,"Alnylam Pharmaceuticals, Inc.",0.0365,5.42,,MA,,ALNY,275,108,208.2,207.5,,,,2327865088.0,19.464,760441024.0,749313984,False,,,-7.127,171.70415,374701.0,,,https://www.alnylam.com,,,02142,,617 551 8101,Henri A. Termeer Square
118,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
119,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
123,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
126,157.36,https://logo.clearbit.com/appliedmaterials.com,0.81857944,0.29132175,3050 Bowers Avenue,,,,157.3,1400.0,5710940.0,6970623.0,5710940.0,1.37974,,157.44,800.0,13.73,,,Santa Clara,[],United States,USD,157.36,2.539,1639526400.0,159.67,157.05,46.975,0.96,0.0061000003,0.533,0.514,7650999808,0.33174,18.385,6.099,140661325824,1645488000,NMS,America/New_York,EST,,148.7398,163.02,86.15,USD,,1.21,885785512,8.85,17.78079,3319124992,,27000.0,,,-18000000,0.47374,10926000000,0.00241,0.81338,,Semiconductor Equipment & Materials,False,,1637712000,0.24,1635638400,,1019001600,2:1,,"Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, display, and related industries. It operates through three segments: Semiconductor Systems, Applied Global Services, and Display and Adjacent Markets. The Semiconductor Systems segment develops, manufactures, and sells various manufacturing equipment that is used to fabricate semiconductor chips or integrated circuits. This segment also offers various technologies, including epitaxy, ion implantation, oxidation/nitridation, rapid thermal processing, physical vapor deposition, chemical vapor deposition, chemical mechanical planarization, electrochemical deposition, atomic layer deposition, etching, and selective deposition and removal, as well as metrology and inspection tools. The Applied Global Services segment provides integrated solutions to optimize equipment and fab performance and productivity comprising spares, upgrades, services, remanufactured earlier generation equipment, and factory automation software for semiconductor, display, and other products. The Display and Adjacent Markets segment offers products for manufacturing liquid crystal displays; organic light-emitting diodes; and other display technologies for TVs, monitors, laptops, personal computers, electronic tablets, smart phones, and other consumer-oriented devices. The company operates in the United States, China, Korea, Taiwan, Japan, Southeast Asia, and Europe. Applied Materials, Inc. was incorporated in 1967 and is headquartered in Santa Clara, California.","Applied Materials, Inc.",us_market,139816402944,1.0,,finmb_251230,,,1635638400,,5888000000,1698710400,32,158.14,,5441999872,0.31465998,0.1438,1.19,408 727 5555,157.98,2.0,11.461035,6.062369,0.25530002,1.673,EQUITY,buy,2,159.67,157.05,158.14,157.98,3585590.0,0.18829,0.51593,0.306,25.344,,Technology,888513024.0,0.0116,10347055.0,1636934400.0,12227767.0,"Applied Materials, Inc.",0.0117,1.23,,CA,,AMAT,208,119,168.18,168,,,,5458999808.0,6.144,5752999936.0,23062999040,False,0.94,0.0059501203,6.4,137.3853,3585590.0,,,https://www.appliedmaterials.com,,,95052-3299,24.5875,,PO Box 58039
127,202.89,https://logo.clearbit.com/ambarella.com,1.2026494,0.29132175,3101 Jay Street,,,,205.0,3200.0,674120.0,741574.0,674120.0,1.122597,,201.0,900.0,14.333,,,Santa Clara,[],United States,USD,202.89,6.804,1639526400.0,206.0,201.3,2.371,,,,,-23882000,-0.07862,-293.084,23.042,6999440896,,NMS,America/New_York,EST,,192.3472,227.59,82.59,USD,,,35078569,1.92,105.671875,36706000,,806.0,,,-18000000,0.62091,135573000,0.052600004,0.84101,,Semiconductor Equipment & Materials,False,,,,1612051200,,,,,"Ambarella, Inc. develops semiconductor solutions for video that enable high-definition (HD) and ultra HD compression, image processing, and deep neural network processing worldwide. The company's system-on-a-chip designs integrated HD video processing, image processing, artificial intelligence computer vision algorithms, audio processing, and system functions onto a single chip for delivering video and image quality, differentiated functionality, and low power consumption. Its solutions enable the creation of video content for wearable cameras; automotive cameras; drones; virtual reality cameras; and internet protocol security cameras for professional use, and home security and monitoring, as well as robotics and industrial application, including identification/authentication cameras, robotic products, and sensing cameras. The company sells its solutions to original design manufacturers and original equipment manufacturers through its direct sales force and distributors. Ambarella, Inc. was incorporated in 2004 and is headquartered in Santa Clara, California.","Ambarella, Inc.",us_market,7507558912,1.0,,finmb_22816801,,,1635638400,,-29707000,1675123200,16,201.3,,30708000,-0.09784,0,1.5,408 734 8888,201.19,2.0,14.155445,24.714699,-0.09779,6.174,EQUITY,buy,2.2,206.0,201.3,201.3,201.19,353056.0,-0.031400003,-0.059899997,0.643,8.408,,Technology,37003100.0,0.0428,1582762.0,1636934400.0,1348757.0,"Ambarella, Inc.",0.044699997,1.67,,CA,,AMBA,260,119,218,227,,,,457760000.0,12.371,12547000.0,303768992,False,,,-0.822,131.29915,353056.0,,,https://www.ambarella.com,,,95054,,408 734 0788,
128,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
129,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
130,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
131,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
132,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
133,35.3122,https://logo.clearbit.com/amcnetworks.com,0.050292373,0.26514983,11 Penn Plaza,,,,35.76,1100.0,544110.0,392409.0,544110.0,1.100259,,35.42,800.0,19.816,,,New York,[],United States,USD,35.3122,2.236,1638230400.0,35.98,34.9,257.28,,,1.179,0.795,856419968,0.28041,4.701,1.318,4025767680,,NMS,America/New_York,EST,,41.52,83.63,32.73,USD,,,29674137,8.14,4.3381076,1391220736,,2002.0,,,-18000000,0.55224997,1521665000,0.0635,1.0390899,42252200,Broadcasting,False,,,,1609372800,,,,,"AMC Networks Inc., an entertainment company, owns and operates a suite of video entertainment products that are delivered to audiences and a platform to distributors and advertisers in the United States and internationally. The company operates in two segments, National Networks; and International and Other. The National Networks segment operates five national programming networks under the AMC, WE tv, BBC AMERICA, IFC, and SundanceTV names. This segment also produces original programming for its programming networks; and licenses, such as programming worldwide, as well as services the national programming networks. The International and Other segment operates a portfolio of channels under the AMCNI name worldwide; subscription streaming business under the Acorn TV, Shudder, Sundance Now, ALLBLK, and AMC+ names; production and comedy venues activities under the Levity name; and film distribution business under the IFC Films name. The company was founded in 1980 and is headquartered in New York, New York.",AMC Networks Inc.,us_market,1492018048,1.0,,finmb_679630,,,1632960000,,328268000,1672444800,13,35.94,,148632992,0.24908,0,-0.31,212-324-8500,35.92,2.0,1.7820044,0.4885177,0.107480004,1.975,EQUITY,hold,3.2,35.98,34.9,35.94,35.92,39863.0,0.087390006,0.31237,0.24,71.499,,Communication Services,30767800.0,0.1426,6025510.0,1635465600.0,5742858.0,AMC Networks Inc.,0.3038,13.26,,NY,,AMCX,68.65,23,48.51,45,,,,870966976.0,20.614,3036017920.0,3054173952,False,,,7.502,50.7309,39863.0,,,https://www.amcnetworks.com,,,10001,4.707038,,
134,143.9,https://logo.clearbit.com/amd.com,0.5725894,0.29132175,2485 Augustine Drive,,,,143.96,1300.0,51805990.0,54435934.0,51805990.0,1.931428,,143.88,1000.0,5.888,,,Santa Clara,[],United States,USD,143.9,2.241,1639526400.0,148.61,143.5507,9.837,,,1.331,1.367,3423000064,0.23047,50.359,11.606,172378652672,798940800,NMS,America/New_York,EST,,141.27,164.46,72.5,USD,,,1200521782,3.34,43.08383,2437625088,,12600.0,,,-18000000,0.46822,4347000000,0.00421,0.70419997,,Semiconductors,False,,,,1608940800,,966902400,2:1,,"Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company operates in two segments, Computing and Graphics; and Enterprise, Embedded and Semi-Custom. Its products include x86 microprocessors as an accelerated processing unit, chipsets, discrete and integrated graphics processing units (GPUs), data center and professional GPUs, and development services; and server and embedded processors, and semi-custom System-on-Chip (SoC) products, development services, and technology for game consoles. The company provides x86 microprocessors for desktop PCs under the AMD Ryzen, AMD Ryzen PRO, Ryzen, Threadripper, AMD A-Series, AMD FX, AMD Athlon, AMD Athlon PRO, and AMD Pro A-Series processors brands; microprocessors for notebook and 2-in-1s under the AMD Ryzen, AMD A-Series, AMD Athlon, AMD Ryzen PRO, AMD Athlon PRO, and AMD Pro A-Series processors brands; microprocessors for servers under the AMD EPYC and AMD Opteron brands; and chipsets under the AMD trademark. It also offers discrete GPUs for desktop and notebook PCs under the AMD Radeon graphics and AMD Embedded Radeon brands; professional graphics products under the AMD Radeon Pro and AMD FirePro graphics brands; and Radeon Instinct and AMD Instinct accelerators for servers. In addition, the company provides embedded processor solutions under the AMD Opteron, AMD Athlon, AMD Geode, AMD Ryzen, AMD EPYC, AMD R-Series, and G-Series processors brands; and customer-specific solutions based on AMD CPU, GPU, and multi-media technologies, as well as semi-custom SoC products. It serves original equipment manufacturers, public cloud service providers, original design manufacturers, system integrators, independent distributors, online retailers, and add-in-board manufacturers through its direct sales force, independent distributors, and sales representatives. Advanced Micro Devices, Inc. was founded in 1969 and is headquartered in Santa Clara, California.","Advanced Micro Devices, Inc.",us_market,173775077376,1.0,,finmb_168864,,,1632528000,,3968999936,1672012800,35,146.16,,3252999936,0.20496,0,1.6,408 749 4000,145.15,2.0,24.439537,11.70045,0.26724002,1.638,EQUITY,buy,2.3,148.61,143.5507,146.16,145.15,49375662.0,0.20934,0.72143996,0.54,12.249,,Technology,1207609984.0,0.0577,69630670.0,1636934400.0,75487134.0,"Advanced Micro Devices, Inc.",0.058000002,1.25,,CA,,AMD,180,101.5,142.5,140,,,,3608000000.0,2.988,702000000.0,14851999744,False,,,3.242,104.3512,49375662.0,,,https://www.amd.com,,,95054,44.386177,,
135,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
137,224.97,https://logo.clearbit.com/amgen.com,-0.0008382797,0.29132175,One Amgen Center Drive,,,,225.95,1100.0,2867110.0,2866328.0,2867110.0,0.615064,,224.8,1300.0,14.543,,,Thousand Oaks,[],United States,USD,224.97,1.643,1639526400.0,227.74,224.8,457.332,7.76,0.0341,-0.035,-0.068,12275999744,0.47642,12.4,5.908,152220827648,1644796800,NMS,America/New_York,EST,,211.6126,276.69,198.64,USD,,2.72,562184431,17.96,12.52617,7394749952,,24300.0,,,-18000000,0.75421995,19265000000,0.00214,0.77197,,Drug Manufacturers—General,False,,1636934400,1.76,1609372800,,943228800,2:1,,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.",Amgen Inc.,us_market,126717952000,1.0,,finmb_24816,,,1632960000,,5608999936,1672444800,25,226.26,,8606000128,0.34998,0.7093,2.28,805 447 1000,226.47,2.0,15.469297,4.9178386,0.21767999,1.192,EQUITY,buy,2.5,227.74,224.8,226.26,226.47,1529585.0,0.08696,0.585,0.044,44.89,,Healthcare,563265984.0,0.0202,11402494.0,1636934400.0,11624960.0,Amgen Inc.,0.020299999,3.64,,CA,,AMGN,298,185,240.24,235,,,,12920999936.0,22.939,37579001856.0,25767000064,False,6.88,0.030379301,9.701,229.97365,1529585.0,,,https://www.amgen.com,,,91320-1799,23.190392,805 447 1010,
138,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
139,24.79,https://logo.clearbit.com/amkor.com,0.64989936,0.29132175,2045 East Innovation Circle,,,,25.0,800.0,791230.0,987549.0,791230.0,1.480519,,24.5,800.0,11.18,,,Tempe,[],United States,USD,24.79,1.481,1639526400.0,24.97,24.66,44.907,0.2,0.0081,0.947,0.963,1235876992,0.21364,5.255,1.123,6494199296,1638748800,NMS,America/New_York,EST,,23.086,29.5,14.82,USD,,,73235277,2.49,9.955824,81992624,,29050.0,,,-18000000,0.19736,900814000,0.63504004,0.40002,,Semiconductors,False,,1638748800,0.05,1609372800,,,,,"Amkor Technology, Inc. provides outsourced semiconductor packaging and test services in the United States, Japan, Europe, the Middle East, Africa, and rest of the Asia Pacific. It offers turnkey packaging and test services, including semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, and test and drop shipment services. The company also provides flip chip scale package products for use in smartphones, tablets, and other mobile consumer electronic devices; flip chip stacked chip scale packages that are used to stack memory, and as applications processors in mobile devices; and flip chip ball grid array products for various networking, storage, computing, and consumer applications. In addition, it offers wafer-level CSP packages that are used in power management, transceivers, sensors, wireless charging, codecs, and specialty silicon; wafer-level fan-out packages for use in ICs; and silicon wafer integrated fan-out technology, which replaces a laminate substrate with a thinner structure. Further, the company provides lead frame packages that are used in electronic devices for low to medium pin count applications; substrate-based wirebond packages, which are used to connect a die to a substrate; micro-electro-mechanical systems (MEMS) packages that are miniaturized mechanical and electro-mechanical devices; and advanced system-in-package modules, which are used in radio frequency and front end modules, basebands, connectivity, fingerprint sensors, display and touch screen drivers, sensors and MEMS, and NAND memory and solid state drives. It primarily serves integrated device manufacturers, fabless semiconductor companies, original equipment manufacturers, and contract foundries. Amkor Technology, Inc. was founded in 1968 and is headquartered in Tempe, Arizona.","Amkor Technology, Inc.",us_market,6061774848,1.0,,finmb_124219,,,1632960000,,553142976,1672444800,2,24.76,,967603968,0.117939994,0.0705,0.46,480 821 5000,24.6,2.0,2.2173524,1.0478932,0.09562001,1.196,EQUITY,buy,2,24.97,24.66,24.76,24.6,894543.0,0.07819,0.2229,0.241,23.767,,Technology,244524992.0,0.0202,4929862.0,1636934400.0,5095732.0,"Amkor Technology, Inc.",0.048600003,5.15,,AZ,,AMKR,28,27,27.5,27.5,,,,790062016.0,3.231,1239277056.0,5784726016,False,0.16,0.006504065,2.269,23.63895,894543.0,,,https://amkor.com,,,85284,10.925518,480 821 8276,
140,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
141,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
142,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
143,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
145,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
146,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
147,3.37,https://logo.clearbit.com/amarincorp.com,-0.333996,0.29132175,Grand Canal Docklands,,,,3.37,2200.0,2958740.0,3614177.0,2958740.0,2.181818,,3.36,3200.0,1.624,,,Dublin,[],Ireland,USD,3.37,2.64,1639526400.0,3.445,3.3,1.628,,,,,18229000,0.030079998,46.995,1.414,856674368,,NGM,America/New_York,EST,,3.9176,9.25,3.11,USD,,,368326699,0.06,56.166664,-59265752,,1000.0,,,-18000000,0.79295,482616000,0.01219,0.31606,,Biotechnology,False,,,,1609372800,,1200614400,1:10,,"Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.",Amarin Corporation plc,us_market,1333933568,1.0,,finmb_407863,,,1632960000,,-2043000,1672444800,7,3.34,,-76620000,0.025810001,0,-9.02,353 1 669 9020,3.35,4.0,2.075123,2.201403,-0.00337,1.723,EQUITY,buy,2.3,3.445,3.3,3.34,3.35,4255320.0,0.0098,-0.00327,-0.092,1.536,,Healthcare,395825984.0,0.044699997,17708472.0,1636934400.0,15978898.0,Amarin Corporation plc,,3.81,,,,AMRN,12,4,7.93,9,,,,479142016.0,1.211,10459000.0,605947008,False,,,-0.011,4.73535,4255320.0,,,https://www.amarincorp.com,,,2,,,Block C 77 Sir John Rogerson's Quay
148,5.41,https://logo.clearbit.com/amyris.com,-0.22507125,0.29132175,5885 Hollis Street,,,,5.41,1800.0,7031610.0,6128096.0,7031610.0,1.580259,,5.41,3200.0,-0.29,,,EmeryVille,[],United States,USD,5.41,0.604,1639526400.0,5.63,5.3,,,,,,-41810000,-0.117189996,-46.182,5.412,1930874496,,NMS,America/New_York,EST,,8.5264,23.42,4.79,USD,,,203332859,-0.22,-24.590908,-15293500,,595.0,,,-18000000,0.41645,14849000,0.35062,0.41973,,Specialty Chemicals,False,,,,1609372800,,1496707200,1:15,,"Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.","Amyris, Inc.",us_market,1667572992,1.0,,finmb_27742428,,,1632960000,,-417134016,1672444800,,5.39,,-49103000,-0.1442,0,,510 450 0761,5.44,2.0,,4.6738877,-1.17278,0.364,EQUITY,none,,5.63,5.3,5.39,5.44,4436714.0,-0.08595,,0.397,1.289,,Basic Materials,308239008.0,0.122600004,37795054.0,1636934400.0,31021197.0,"Amyris, Inc.",0.1876,5.72,,CA,,AMRS,,,,,,,,114887000.0,0.373,338099008.0,356784992,False,,,-1.506,13.2401,4436714.0,,,https://www.amyris.com,,,94608,,510 225 2645,Suite 100
